Annals of Oncology **12**: 1769–1794, 2001.

Index of subjects Volume 12 (2001)

A
acromegaly
  diagnosis (Review) S2: 89
  GHRH-mediated (Review) S2: 89
  treatment (Review) S2: 89
ACTH
  clinical heterogeneity S2: 83
  extrapituitary source S2: 83
  molecular bases S2: 83
acute lymphoblastic leukemia
  development of rhinocerebral zygomycosis (Clinical case) 415
  in children (Review) 587
  MRD detection (Review) 587
  M6 subtype 451
  PCR-based techniques (Review) 587
  prognostic factors 451
  risk assessment (Review) 587
  treatment effects 455
acute myelocytic leukemia
  and breast cancer 203
adenocarcinoma of the prostate
  treatment with
    docetaxel 1273
adenovirus
  as a treatment for patients with
    pancreatic cancer 379
  increasing tumor regression 379
adhesion molecules
  in a patient with
    indolent breast cancer (Clinical case) 1019
adjuvant chemotherapy
  after breast conserving surgery 373
  as a treatment for patients with
    breast cancer 1011, 1081, S3: 15
    colorectal cancer (Review) 13, 239, (Review) 887
    gastric cancer (Letter to the editor) 1179
    melanomas (Review) 1663
    non-small-cell lung cancer 807
  dose-intensity 373
  quality of life S3: 15
  S-phase fraction 239
  surgical management (Review) 887
  thymidylate synthase 239
  tumor resistance 239
  vascular endothelial growth factor expression 239
  with
    interferon-alpha 1663
adriamycin
  in combination with
    cyclophosphamide and dexamethasone 105
    etoposide and cisplatin 1011
  as a treatment for patients with
    advanced multiple myeloma 105
    breast cancer 1011
advanced
  cancer
    treatment with
      high-dose progestins 289
  colorectal cancer
    dose intensity 1269
    ESMO minimum clinical recommendations (Special article) 1055
    second-line treatment 1269
    treatment with
      irinotecan 1269
  gastric cancer
    treatment with
      docetaxel and cisplatin 47
  seminoma
    prognosis 487
    treatment with
      cisplatin and etoposide 487
adverse events
  caused by DMSO and cell lysis 505
  of trastuzumab S1: 63
aggressive lymphomas
  prognosis 513
  treatment with
    front-line intensive sequential chemotherapy 513
alkaline phosphatase
  immunohistochemistry (Clinical case) 1485
alkylating agents
  as a treatment for patients with
    brain tumors 249
alveolar soft part sarcoma
  pancreatic metastasis (Clinical case) 865
ameloblastoma
  treatment with
    paclitaxel and carboplatin (Clinical case) 1489
amifostine
  as a protection against toxicities 1151
  in patients with
    germ cell tumor 1151
    oxaliplatin-related peripheral sensitive neuropathy 421
  subcutaneous administration (Letter to the editor) 421
anal cancer
  treatment with
    radiation therapy and chemotherapy 397
anaplastic large-cell lymphoma
  classification 853
anastrozole
  as a treatment for patients with
    breast cancer 1539
  failure 1539
androgen receptor
  in human prostate cancer (Review) S2: 141
angiogenesis
  inhibited by thalidomide 987
  role of malignant ascites (Review) 1353
anorexia-cachexia syndrome
  treatment with

high-dose progestins (Review) 289
anthracycline
as a treatment for patients with
non-Hodgkin's lymphoma 457
pancreatic cancer 1399
primary non-Hodgkin's lymphoma of the liver 1005
inducing lesions in mice 405
inhibited by dexrazoxane 405
anthracycline-associated acute cardiotoxicity
clinical symptoms 963
in adults treated for leukemia 963
pathological findings 963
anthracycline-refractory
breast cancer 1255
antibiotics
reduced by ciprofloxacin and roxithromycin 1359
anticancer agents
clearance (Review) 1515
anti-HER2 monoclonal antibody
in HER2-positive tumors S1: 81, 89, 95
antimetastatic properties
of matrix metalloproteinase inhibitors 389
apoptosis
as predictors of response to chemotherapy 799
expression of ax1 819
5-fluorouracil induced Fas regulation 209
in
breast tissue 819
high-risk B-cell chronic lymphocytic leukemia 981
liver metastasis 209
non-small-cell lung cancer 799
aromatase inhibitors
as a treatment for patients with
breast cancer 1539
ascites
as a result from peritonitis carcinomatosa (Review) 1353
autoimmune disease
response in patients with
gastric MALT-lymphoma 937
autologous stem-cell transplantation
in solid tumors (Letter to the editor) 131
autotransplant
as first-line treatment for patients with
non-Hodgkin's lymphoma 1749
tandem 1749
aza-anthracenedione
as a treatment for patients with
non-Hodgkin's lymphoma 661
tolerated dose 661

B

bad news
breaking 364
basic fibroblast growth factor
interference as a therapeutic target (Review) 1353
BBR 2778
as a treatment for patients with
non-Hodgkin's lymphoma 661
tolerated dose 661
B-cell chronic lymphocytic leukemia
apoptosis 981
overexpression of the p73 gene 981
B-cell lymphoma
remission (Clinical case) 1169
transformation of Hodgkin's disease (Clinical case) 1169
BCL-2 expression
in patients with non-Hodgkin's lymphoma 109
translocation 109
biliary tract cancer
treatment with
gemcitabine 183
biliary tree cancer
treatment with
irinotecan 501
bioavailability
in patients with
solid tumors 1643
of oral vinorelbine 1643
biochemical modulation
in patients with gastrointestinal cancer 1581
bioequivalence
of oral vinorelbine 1643
biological
effects
of oxytocin in cancer cells S2: 37
markers
identification in breast cancer 615
bisphosphonates
as a treatment for patients with
metastatic bone disease 1423
optimum schedule 1433
bladder cancer
organ preservation 923
treatment with
synchronous chemoradiotherapy 929
blood cell count
in patients with
soft tissue sarcomas 1423
prognostic significance 1423
relation with cytokine serum levels 1423
Bloom's syndrome
treatment with
radiochemotherapy (Clinical case) 1015
in combination with
head and neck cancer (Clinical case) 1015
body mass index
correlation with
oral cancer 331
pharyngeal cancer 331
squamous cell oesophageal cancer 975
bone marrow transplantation
as a treatment for patients with
non-small-cell lung cancer 1553
ovarian cancer 693
in combination with
high-dose chemotherapy 693
bone pain
treatment with

clodronate 1433
pamidronate 1433
brain tumors
recurrent 255
treatment with
cisplatin and vinorelbine 59
temozolomide 249, 255
BRCA1
as a predictive factor for breast cancer (Review) 895
breast cancer
acute myeloid leukemia 203
anthracycline-refractory 1255
apoptosis 819
axl expression 819
biological
markers 615
breast conserving therapy (Letter to the editor) 723, 997, 1075, 1527
carcinocythemia (Clinical case) 1019
cardiac toxicity 1067
central nervous system involvement 353
conserving surgery 373
detection by RT-PCR 39
diagnosis (Clinical case) 267
dose-intensity 373
epidermal growth factor receptor 841
estrogen receptors 819
follow-up examinations 1107
future directions S1: 75
glycemic index (Editorial) 1507, 1533
glycemic load 1533
hereditary 1699
HER2 overexpression S1: 9, 15, 23
hormone replacement therapy (Review) 301
hyperinsulinemia (Editorial) 1507
letrozole 1539
life expectancy 1107
lobular cancer (Clinical case) 715
lymph nodes 1091
markers 1693
metastatic 69, 237, 1259, S1: 49
myeloid metaplasia (Clinical case) 267
overexpression of c-erbB-2 oncoprotein 525
prior exposure to anthracyclines 1061
prognostic factors 39, 231, 525, 841, S1: 23
psychosocial factors 469
quality of life 1461, S3: 15
rectal metastases (Clinical case) 715
risks (Editorial) 1507, 1533
RT-PCR detection 1693
sentinel node biopsy (Letter to the editor) 723
staging (Letter to the editor) 1653
survival 39, S3: 15
treatment approach (Clinical case) 267
treatment with
adjuvant radio-chemotherapy 373, 1011, S3: 15
adjuvant therapy 1081
adriamycin, cyclophosphamide, etoposide and cisplatin 1011
aromatase inhibitors 1539
capecitabine 1274
capecitabine and paclitaxel 605
chemoendocrine adjuvant chemotherapy 685
cisplatin, vinorelbine and continuous 5-fluorouracil 95
cisplatin and trastuzumab S1: 49
CMF 1274
continuous 5-fluorouracil and cisplatin 95
cytokeratin 39
docetaxel 1393
docetaxel and epirubicin 353, 1097
docetaxel and gemcitabine 1259
docetaxel and vinorelbine 909, 1061
docetaxel, mitoxantrone and G-CSF 793
doxorubicin and paclitaxel 1067
EMP 1265
eniluracil and fluorouracil 1255
epirubicin and cyclophosphamide 1081
epirubicin and paclitaxel (Review) 593
formestane 1539
formestane and MMM 685
Herceptin S1: 15, 49
HER-2 15, 49
hormone therapy 1539
letrozole 1527, 1539
paclitaxel 1545
radiotherapy 997, 1091
Targit 1075
taxotere 353
trastuzumab S1: 15, 75, 1545
vinorelbine 1677, 1683
breast conserving therapy
Targit, 997, 1075
breast self-examination (Letter to the editor) 573

C
CAELYX
as a treatment for patients with
pancreatic cancer 1399
cachexia syndrome
treatment with
high-dose progestins (Review) 289
CA19-9
as a monitoring parameter in metastatic colorectal cancer 221
CA125
as a prognostic factor for relapsed epithelial ovarian cancer 1705
camptothecin analog
dose-finding 1631
pharmacokinetics 1631
capecitabine
as a treatment for patients with
breast cancer 605, 1274
colorectal cancer 1737
dose limitations 1737
in combination with
oxaliplatin 1737
paclitaxel 605
inducing coronary spasm 723
versus CMF 1274
capillary leak syndrome
induced by gemcitabine (Clinical case) 1651

carbohydrate
as a risk factor for breast cancer 1533
carboplatin
as a treatment for patients with
ameloblastoma (Clinical case) 1489
limited disease small-cell lung cancer 1231
non-small-cell lung cancer 193
ovarian cancer 1115
small-cell lung cancer 647, 787, 957
solid tumors 549
urothelial carcinoma 947
high-dose 647
in combination with
cisplatin 647
etoposide 957, 1231
gemcitabine 947, 1115
hyperfractionated thoracic radiation therapy 1231
ifosfamide and paclitaxel 787
paclitaxel 193, (Clinical case) 1489
paclitaxel and topotecan 549
carcinoid tumors
as a source of ACTH S2: 83
ectopic secretion of GHRH (Review) S2: 89
epidemiology 1295
in Dutch patients 1295
significance of blood chromogranin A measurement S2: 69
survival 1295
carcinoid syndrome
related to hormone hyperproduction (Review) S2: 95
carcinomatous meningitis
as a clinical manifestation of
pancreatic cancer (Clinical case) 1757
in combination with
gastric linitis adenocarcinoma (Clinical case) 869
cardiovascular disease
hormone replacement therapy (Review) 301
cardiotoxicity
after treatment with
doxorubicin, paclitaxel and cisplatin 1743
trastuzumab S1: 63
in patients with
advanced solid tumors 1743
case-control study
socio-economic correlates of cancer 327
caspases
role in apoptosis 799
catalytic inhibitor
of anthracycline induced lesions 405
CD3
as a molecular fingerprint for B cells tumors 1479
CD20 antigen
in transformation of Hodgkin's disease to high-grade B-cell lymphoma (Clinical case) 1169
CEA
as a monitoring parameter in metastatic colorectal cancer 221
cell-cycle
arrest
in patients with colorectal cancer 209
carcinocythemia (Clinical case) 1019
in a patient with indolent breast cancer (Clinical case) 1019
role of 4D5-mediated inhibition of HER2 receptor signalling S1: 21
cell proliferation
predisposed by genetic syndromes (Review) S2: 3
central nervous system
involvement in patients with breast cancer 353
risk factors 685
treatment with taxotere 353
c-erbB-2 oncoprotein overexpression
as a prognostic factor 525
in patients with breast cancer 525
c-erbB-4 overexpression
in patient with non-small-cell lung cancer 1127
response to gemcitabine-cisplatin chemotherapy 1127
cerebrospinal fluid
as a clinical manifestation of carcinomatous meningitis (Clinical case) 869
effect of topotecan infusion (Clinical case) 119
reactivation of chronic hepatitis B infection (Clinical case) 123
small-cell carcinoma of the esophagus 1321
cervical cancer
HPV testing (Review) 1511
treatment with
cisplatin (Editorial) 883
cisplatin and gemcitabine 541
cervix cancer
treatment with
cisplatin combination chemotherapy 967
chemoendocrine adjuvant therapy
as a treatment for patients with
breast cancer 685
chemoradiation
as a treatment for patients with
pancreatic cancer 681
in combination with
5-fluorouracil 681
chemoradiotherapy 349
as a treatment for patients with
bladder cancer 929
laryngeal cancer 343
rectal cancer (Review) 1039
associated with valproate 217
in combination with
sequential induction chemotherapy 343
chemosensitivity
correlation with NE-differentiated tumors (Review) S2: 119
dose intensity 357, 373
drug resistance (Review) 23
nitroso-urea-cisplatin based 217
retreatment (Review) 23
second line 255
survival rate of patients with
breast cancer 231
toxicity 217
childhood
head and neck cancer
prognosis 1157
tumor staging 1157
leiomyosarcoma 1163

cholangiocarcinoma
treatment with
irinotecan 501
chondrosarcoma
of bone 859
treatment with
surgery 859
CHOP
as a treatment for patients with
diffuse large B-cell lymphoma (Clinical case) 1327
nasal NK/T-cell lymphoma 349
chromogranin A
as a biological marker for gastroenteropancreatic endocrine tumors (Review) S2: 95
as a circulating marker S2: 73, (Review) S2: 153, S2: 159
as a marker for prostate cancer (Review) S2: 135, (Review) S2: 153
clinical significance S2: 69, 73, 79, (Review) S2: 119
correlation with NE differentiation (Review) S2: 119, 159
in neuroendocrine tumors S2: 69, 73, 79
potential clinical value (Review) S2: 153
chromosome aberrations
after treatment with etoposide and cisplatin (Short report) 897
chronic hepatitis B
treatment with
lamivudine (Clinical case) 123
chronic lymphocytic leukemia
correlation with paraneoplastic pemphigus (Clinical case) 115
prognostic role of the serum thymidine level 621
treatment with
fludarabine 621
fludarabine and mitoxantrone 1455
chronomodulation
in patients with
gastrointestinal cancer 1581
chronotherapy
as a treatment for patients with
pancreatic cancer 681
ciprofloxacin
as a treatment for patients with
small-cell lung cancer (Editorial) 1339
in combination with roxithromycin (Editorial) 1339, 1359
reducing febrile leucopenia (Editorial) 1339, 1359
circulant tumor cells
in a patient with indolent breast cancer (Clinical case) 1019
cisplatin
as a treatment for patients with
advanced non-small-cell lung cancer 1221
advanced seminoma 487
anal cancer 397
brain metastasis 59
breast cancer 1011, S1: 49
cancer with unknown primary site 535
cervical cancer 541, (Editorial) 883
cervix cancer 963
endometrial cancer 767
gastric cancer 47, 1407
head and neck cancer 199, 357, 493
mesothelioma 201
metastatic breast cancer 95
non-small-cell lung cancer 59, 1127, 1369, 1671
oesophageal cancer 1407
ovarian cancer 1705
small-cell lung cancer 463, (Editorial) 585, 647
solid tumors 1743
squamous-cell cancer of head and neck 199
benefits 1671
combination chemotherapy 967, 1671
correlation with c-erbB-4-receptor expression 1127
effect on growth 493
high-dose 647
in combination with
adriamycin, cyclophosphamide and etoposide 1011
BEMP 967
carboplatin 647
continuous infusion fluorouracil 535
continuous infusion fluorouracil and vinorelbine 95
docetaxel 47, 199
doxorubicin and paclitaxel 1743
epirubicin and raltitrexed 1407
etoposide 463, 487, 1705
5-fluorouracil 397
gemcitabine 541, 1127
gemcitabine, paclitaxel and vinorelbine 1369
paclitaxel and etoposide 463
raltitrexed 357
trastuzumab S1: 45
vindesine 1221
vinorelbine 59, 95, 767
quality of life 1671
survival 1671
versus gemcitabine 1221
classification
R.E.A.L. 853
clinical benefits
quality (Editorial) 1191, S3: 3
response in patients with non-small-cell lung cancer 1221
clinical cases
acute lymphoblastic leukemia
development of rhinocerebral zygomycosis 415
adhesion in molecules
in a patient with
indolent breast cancer 1019
alkaline phosphatase
immunohistochemistry 1485
alveolar soft part sarcoma
pancreatic metastases 865
ameloblastoma
treatment with
paclitaxel and carboplatin 1489
B-cell lymphoma
remission 1169
transformation of Hodgkin's disease 1169
Bloom's syndrome
treatment with
radiochemotherapy 1015
in combination with
head and neck cancer 1015
breast cancer

carcinocythemia 1019
diagnosis 267
lobular cancer 715
myeloid metaplasia 267
rectal metastases 715
treatment approach 267
capillary leak syndrome
induced by gemcitabine 1651
carboplatin
as a treatment for patients with
ameloblastoma 1489
in combination with
paclitaxel 1489
carcinomatous meningitis
as a clinical manifestation of
pancreatic cancer 1757
in combination with
gastric linitis adenocarcinoma 869
CD20 antigen
in transformation of Hodgkin's disease 1169
cell cycle
carcinocythemia 1019
in a patient with
indolent breast cancer 1019
cerebrospinal fluid
as a manifestation of carcinomatous meningitis 869
effect of topotecan infusion 119
small-cell carcinoma of the esophagus 1321
CHOP
as a treatment for patients with
reactivation of chronic hepatitis B infection 123
chronic hepatitis B
treatment with
lamivudine 123
chronic lymphocytic leukemia
correlation with paraneoplastic pemphigus 115
circulant tumor cells
in a patient with
indolent breast cancer 1019
complete response
after treatment with
MAID chemotherapy 271
of sarcomatoid renal-cell carcinoma 271
computerized tomography
compared to PET 719
for patients with
Hodgkin's disease 719
pitfalls 719
conjunctivis
correlation with chronic lymphocytic leukemia 115
corticosteroids 123
diffuse large B-cell lymphoma
treatment with
CHOP 1327
dihydropyrimidine dehydrogenase
deficiency 569
role of 5-fluorouracil 569, 919
docetaxel
eccrine porocarcinoma 411
doxorubicin
as a treatment for patients with
sarcomatoid renal-cell carcinoma 271
complete response 271
eccrine porocarcinoma
treatment with
docetaxel 411
esophagus
treatment with
chemotherapy 1321
fulminant hepatitis
reactivation 123
treatment with
lamivudine 123
5-fluorouracil
DHD-deficiency 569
fungal infection
in patients with
acute lymphobalstic leukemia 415
gastric adenocarcinoma
in association with carcinomatous meningitis 869
gastric cancer
complete response 275
treatment with
liposomal daunorubicin 275
gemcitabine
in combination with
vinorelbine 1761
inducing a capillary leak syndrome 1651
toxicity 1651
hand–foot syndrome
after treatment with
gemcitabine and vinorelbine 1761
head and neck cancer
locally advanced 1015
radiation therapy 1015
Hodgkin's disease
transformation to high-grade B-cell lymphoma 1169
treatment with
Rituximab 1169
immunohistochemistry
alkaline phosphatase 1485
immunosuppression
in chronic hepatitis B infection 123
interferon
as a treatment for patients with
non-Hodgkin's lymphoma 123
in combination with
vindesine 483
intramedullary metastasis
in renal cell cancer 1173
irinotecan
as a treatment for patients with
metastatic colon cancer 569
in combination with
oxaliplatin and raltitrexed 569
Kaposi's sarcoma
complete response 274
treatment with

liposomal daunorubicin 275
liposomal doxorubicin
as a treatment for patients with
gastric Kaposi's sarcoma 275
complete response 275
lobular cancer
of the breast 715
rectal metastases 715
MAID chemotherapy
as a treatment for patients with
sarcomatoid renal-cell carcinoma 271
complete response 271
malignant ameloblastoma
treatment with
paclitaxel and carboplatin 1489
methotrexate
as a treatment for patients with
gastric adenocarcinoma 869
moulds
causing fungal infection 415
neutropenic fever
caused by fungal infections 415
non-small-cell lung cancer
hand–foot syndrome 1761
oxaliplatin
as a treatment for patients with
colorectal cancer 569
in combination with
irinotecan and raltitrexed 569
paclitaxel
as a treatment for patients with
malignant ameloblastoma 1489
in combination with
carboplatin 1489
pancreatic cancer
occurrence of carcinomatous meningitis 1757
pancreatioduoenectomy
as a treatment for patients with
alveolar soft-part sarcoma 865
papillary cancer
in a man 563
of the peritoneum 563
pathology 563
paraneoplastic pemphigus
as the presentation of CLL 115
peritoneal carcinomatosis
complete response 275
gastric Kaposi's sarcoma 275
treatment with
liposomal daunorubicin 275
peritoneal neoplasm
in a man 563
pharmacokinetics 119
plasma exchange 123
posterior leukoencephalopathy syndrome
following CHOP chemotherapy 1327
pulmonary toxicity
induced by gemcitabine 1651
radiation therapy
as a treatment for patients with
renal cell carcinoma 1173
diagnosis of ISCM 1173
raltitrexed
as a treatment for patients with
colorectal cancer 569
in combination with
irinotecan and oxaliplatin 569
rectal cancer
from lobular cancer of the breast 715
renal cell cancer
intramedullary spinal cord metastasis 1173
rhinocerebral zygomycosis
in patients with
acute lymphoblastic leukemia 415
Rituximab
as a treatment for patients with
non-Hodgkin's lymphoma 1169
remission 1169
sarcoidosis
immunohistochemical staining pattern 1485
signet-ring cell adenocarcinoma
in gastric adenocarcinoma 869
sarcomatoid renal-cell carcinoma
complete response 271
treatment with
doxorubicin 271
MAID chemotherapy 271
small-cell carcinoma
of the esophagus 1321
treatment with
chemotherapy 1321
spinal cord tumors
in renal cell carcinoma 1173
staging
of Hodgkin's lymphoma 719
stomatisis
correlation with chronic lymphocytic leukemia 115
Taxotere
as a treatment for patients with
eecrine porocarcinoma 411
testicular cancer
PET 1485
PLAP 1485
role of sarcoidosis 1485
tomography
in suspected testicular cancer relapse 1485
role of sarcoidosis 1485
topotecan infusion
effect on cerebrospinal fluid 119
tumor
expression of somatostatin receptor subtype
association with SIADH 1061
in patients with
small-cell lung cancer 1061
vinorelbine
hand–foot syndrome 1761
in combination with
gemcitabine 1761

clinical guidelines
potential and pitfalls (Editorial) 1189
clodronate
as a treatment for patients with
metastatic bone disease 1433
in combination with
pamidronate 1433
CMF
as a treatment for patients with
breast cancer 1274
versus capecitabine 1274
collagen crosslinks
measurement of bone resorption 1433
colon-rectal carcinoma
adjuvant therapies (Letter to the editor) 1331
colony-stimulating factors
cell washing 505
colorectal cancer
advanced 1269
apoptosis in liver metastases 209
clinical outcome 779
dietary glycemic load 173
fiber intake 173
growth modulation index 187
hepatic metastases (Review) 887
hereditary (Review) 151, 813
in elderly patients (Review) 435
liver metastases 779
mcl-1 expression 779
microsatellite instability (Review) 151, 813
monitoring with CEA and CA 19-9 221
p53 expression 779
Rb expression 779
resistance to 5-fluorouracil (Letter to the editor) 575, 779
second line treatment 709
S-phase fraction 239
surgery 1721
survival 1721
thymidylate synthase 239
treatment with
adjuvant chemotherapy 239, (Review) 887
capecitabine and oxaliplatin 1737
chemotherapy (Review) 435
combination chemotherapy (Letter to the editor) 278
5-fluorouracil 779
5-fluorouracil, oxaliplatin and leucovorin 669
5-fluorouracil and folinic acid 1721
5-fluorouracil and leucovorin (Review) 13
5-fluorouracil and oxaliplatin 187, 519
5-fluorouracil induced Fas upregulation 209
5-fluorouracil on a 24-hour weekly basis 321
hepatic arterial infusion, folinic acid and 5-fluorouracil 599
intra-arterial hepatic chemotherapy (Letter to the editor) 1023
oxaliplatin and raltitrexed 709
vascular endothelial growth factor 239
combination therapy
as a treatment for patients with
breast cancer S1: 43
gastric cancer 47
CHOP and field radiation 349
communication
with patients 365
comorbidity
effect of chemotherapy 957
in elderly patients 957
complete response
after treatment with
MAID chemotherapy (Clinical case) 271
of sarcomatoid renal cell carcinoma (Clinical case) 271
computerized tomography
compared to PET (Clinical case) 719
for patients with
Hodgkin's disease (Clinical case) 719
osteosarcoma 1601
pulmonary metastases 1601
pitfalls (Clinical case) 719
conjunctivitis
correlation with chronic lymphocytic leukemia (Clinical case) 115
consensus primers
identification of B-cell tumor-specific molecular fingerprint 1479
continuous infusion fluorouracil
as a treatment for patients with
metastatic breast cancer 95
in combination with
cisplatin and vinorelbine 95
coronary spasm
induced by capecitabine (Letter to the editor) 723
corticosteroids (Clinical case) 123
cortisol
role in ectopic ACTH syndrome S2: 83
CPC
as a treatment for patients with
ovarian cancer 1411
neurotoxicity 1411
CPT-11
dose-finding 1631
pharmacokinetics 1631
cryopreservation
caused by cell lysis 505
CUP
ESMO minimum clinical recommendations 1057
localised disease 1605
management (Editorial) 431
PET 1605
treatment
with cisplatin, continuous infusion 5-FU and etoposide 535
Cushing's syndrome
as a type of ectopic ACTH syndrome S2: 83
clinical and biochemical features S2: 83
cutaneous malignant melanoma
classification (Editorial) 9
cyclophosphamide
as a treatment for patients with
advanced multiple myeloma 105
breast cancer 1011, 1081
pancreatic cancer 379
in combination with
adenovirus 379

adriamycin, etoposide and cisplatin 1011
epirubicin 1081
cytarabine
as a treatment for patients with
non-Hodgkin's lymphoma 1439
in combination with dexamethasone and oxaliplatin 1439
cytochrome p450
as a treatment for patients with
pancreatic cancer 379
in combination with
CYP2B1/cyclophosphamide 379
cytokeratin
as a treatment for patients with
breast cancer 39
cytokine
regulated by neuropeptides (Review) S2: 19
secretion (Review) S2: 19
serum level
relation with blood cell count 1423
T-cell receptors (Review) S2: 19
cytostatic drug therapy
for patients with
Ewing tumors 1619
second malignancies 1619

D

dacarbazine
as a treatment for patients with
pancreatic cancer 1139
DACH-platinum
as a treatment for patients with ovarian cancer 1411
neurotoxicity 1411
deoxycytidine
maximum tolerated dose 627
dexamethasone
as a treatment for patients with
advanced multiple myeloma 105, 991
non-Hodgkin's lymphoma 1439
in combination with
adriamycin and cyclophosphamide 105
cytarabine and oxaliplatin 1439
thalidomide 991
dexrazoxane
as a inhibitor of anthracycline induced lesions 405
diagnosis
breaking bad news 365
diarrhea
chemotherapy-induced 227
treatment with
octreotide 227
diffuse large B-cell lymphoma
classification 853
treatment with
CHOP (Clinical case) 1327
digestive neuroendocrine tumor
growth factors (Review) S2: 13
oncogenes (Review) S2: 13
proliferation markers (Review) S2: 13
receptor expression (Review) S2: 13
dihydropyrimidine dehydrogenase
deficiency (Clinical case) 569
role of 5-fluorouracil (Clinical case) 569, 919
dimethyl sulfoxide-free peripheral blood progenitor cells
in patients with breast cancer 505
intensified chemotherapy 505
disease-free survival
of patients with Hodgkin's lymphoma 29
disease management
platinum drugs 1195
docetaxel
as a treatment for patients with
advanced
breast cancer 353, 1097, 1259
gastric cancer 47
breast cancer 793, 909, 1061, 1393, S1: 69
eccrine porocarcinoma (Clinical case) 411
head and neck cancer 199
non-small-cell lung cancer 89, (Review) 739
pancreatic cancer 101
prostate cancer 633, 1273
soft tissue sarcoma 1281
squamous-cell cancer of head and neck 199
in combination with
cisplatin 47, 199
estramustine and hydrocortisone 633
epirubicin 353, 1097
gemcitabine 89, 101, 1259
mitoxantrone and G-CSF 793
paclitaxel 739
trastuzumab S1: 69
vinorelbine 909, 1061
dolastatin
as a treatment for patient with
malignant melanomas 509
dose
density
after breast conserving surgery 373
escalation 471
using haematopoietic growth factors 471
finding
of irinotecan 1631
intensity
after breast conserving surgery 373
down-sizing
chemoradiation therapy (Review) 1039
doxorubicin
as a treatment for patients with
breast cancer 1067
sarcomatoid renal cell carcinoma (Clinical case) 271
solid tumors 1743
complete response (Clinical case) 271
in combination with
cisplatin and paclitaxel 1743
paclitaxel 1067
lyposomal 1743
tests S1: 101
DPD
relationship with 5-fluorouracil disposition and toxicity 1301

treatment tolerability 1301
drinking
correlation with
oral cancer 331
pharyngeal cancer 331
squamous cell oesophageal cancer 975
drop out problems
in quality of life research S3: 11
drug distribution
in patients with
non-small-cell lung cancer 1553
drug resistance (Review) 23

E
EBV
as a risk factor for developing posttransplant lymphoproliferative disorders 831
eccrine porocarcinoma
treatment with
docetaxel (Clinical case) 411
ectopic secretion
ACTH syndrome S2: 83
versus eutropic secretion S2: 83
elderly patients
comorbidity 957
geriatric assessment S3: 49
mortality 1467
quality of life S3: 49
treatment with
chemotherapy (Review) 435, 957
etoposide and carboplatin 957
with
colorectal cancer (Review) 435
small-cell lung cancer 957
ELISA
HER2 tests S1: 97
endocrine glands
deregulation of genetic pathways (Review) S2: 3
endocrine pancreatic tumors
treatment with
radionuclide therapy 941
endometrial cancer
treatment with
cisplatin and vinorelbine
eniluracil
as a treatment for patients with advanced
breast cancer 1255
head and neck cancer 919
in combination with
5-fluorouracil 919, 1235
EORT classification 853
epidemiology
in patients with
carcinoid disease 1295
relation with ovarian cancer 337
epidermal growth factor receptor mutation
as a therapeutic target (Review) 745
biological significance (Review) 745
prognostic value 841
epirubicin
as a treatment for patients with
breast cancer 69, 81, 353, (Review) 593, 1081, 1097, S1: 69
gastric cancer 1407
oesophageal cancer 1407
high-dose 1035
in combination with
cisplatin and raltitrexed 1407
cyclophosphamide 1081
docetaxel 353, 1097
paclitaxel 69, (Review) 593
trastuzumab S1: 69
erbB-2
in patients with
breast cancer S1: 9
E7070
as a treatment for patients with
solid tumors 1289
ESMO recommendations
for application of
haematopoietic growth factors (Special article) 1219
for diagnosis, treatment and follow-up of patients with
advanced colorectal cancer (Special article) 1055
colon cancer (Special article) 1053
CUP (Special article) 1057
Hodgkin's lymphoma (Special article) 1213
non-Hodgkin's lymphoma (Special article) 1209
non-seminomatous germ cell tumors (Special article) 1215
non-small-cell lung cancer (Special article) 1049
ovarian cancer (Special article) 1205
primary breast cancer (Special article) 1047
small-cell lung cancer (Special article) 1051
testicular seminoma (Special article) 1217
for prophylaxis of chemotherapy-induced nausea and vomiting (Special article) 1059
process (Editorial) 1037
esophageal endoscopy
in patients with
head and neck cancer 643
esophagus
treatment with
chemotherapy (Clinical case) 1321
estramustine
as a treatment for patients with
advanced breast cancer 1265
prostrate cancer 633
in combination with
docetaxel and hydrocortisone 633
estrogen receptors
in breast tissue 819
etoposide
as a treatment for patients with
breast cancer 1011
CUP 535
limited disease small-cell lung cancer 1231
small-cell lung cancer 1567
ovarian cancer 1705
small-cell lung cancer 463, 835
in combination with

carboplatin 1231
cisplatin 1705
cisplatin and continuous infusion 5-FU 535
cisplatin, adriamycin and cyclophosphamide 1011
cisplatin and paclitaxel 463
gemcitabine 835
hyperfractionated thoracic irradiation 1231
topotecan 1567
etoposide phosphate
as a treatment for patients with
small-cell lung cancer 957
comorbidity in elderly patients 957
in combination with
carboplatin 957
extravasation
of anthracycline 405
evidence-based medicine
randomized trials 1611
Ewing's sarcoma
cytostatic drug therapy 1619
FDG-PET *versus* spiral CT 479

F
Fas upregulation
associated with apoptosis in liver metastases 209
induced by 5-fluorouracil 209
in patients with colorectal cancer 209
FDG-PET
as a means to predict the survival rate 29
to detect
pulmonary metastases 479
staging of non-Hodgkin's lymphomas 825
versus spiral CT 479
female hormones
relation with ovarian cancer 337
fiber intake
colorectal cancer risk 173
field radiation
as a treatment for patients with
nasal NK/T-cell lymphoma 349
in combination with
CHOP 349
first-line therapy
as a treatment for patients with
HER2-positive metastatic breast cancer S1: 57
non-Hodgkin's lymphoma (Short report) 363
FISH
HER2-tests S1: 97
5-fluorouracil
as a treatment for patients with
advanced
colorectal cancer 187, 519
pancreatic cancer 675
anal cancer 397
breast cancer 95, 605, 1255
colorectal cancer 13, 209, 221, 569, 599, 669, 1721
gastric cancer 1575
gastrointestinal cancer 1581
head and neck cancer 919
liver metastasis 321
squamous-cell cancer of head and neck 919
continuous infusion 95
DHD-deficiency (Clinical case) 569
in combination with
cisplatin 397
cisplatin and vinorelbine 95
eniluracil 919, 1255
folinic acid 221, 1721
folinic acid and hepatic arterial infusion 599
irinotecan and leucovorin 1575
leucovorin and oxaliplatin 669
leucovorin and gemcitabine 675
oxaliplatin 187, 519
inducing Fas upregulation 209
oral 919
relation with DPD 1301
treatment schedule 1301
toxicity 1301
versus capecitabine and paclitaxel 605
weekly 24-hour infusion 221, 321
fludarabine
as a treatment for patients with
chronic lymphocytic leukemia 1455
non-Hodgkin's lymphoma 1455
opportunistic infections 1455
fluorine-18 fluorodeoxyglucose scintigraphy
to detect the staging of
non-Hodgkin's lymphoma 825
fluorodeoxyglucose
used for PET 719
folinic acid
as a treatment for patients with
colorectal cancer 221, 599, 1721
in combination with
5-fluorouracil 221, 1721
5-fluorouracil and hepatic arterial infusion 599
follicle-stimulating hormone
for patients with Hodgkin's disease 1307
follicular lymphoma
identification using consensus primer 1479
follow-up examinations
impact on life expectancy 1107
formestane
as a treatment for patients with
breast cancer
in combination with
MMM 685
4D5 antibody
in anti-HER2 monoclonal antibody S1: 21
free radical scavenger 405
fulminant hepatitis
reactivation (Clinical case) 123
treatment with
lamivudine (Clinical case) 123
fungal infection
in patients with acute lymphoblastic leukemia (Clinical case) 415

G

gall bladder cancer
  treatment with
    gemcitabine 1403
    irinotecan 501
gastric adenocarcinoma
  in association with carcinomatous meningitis (Clinical case) 869
  treatment with
    epirubicin, cisplatin and raltitrexed 1407
gastric cancer
  complete response (Clinical case) 275
  treatment with
    adjuvant chemotherapy (Letter to the editor) 1179
    docetaxel and cisplatin 47
    5-fluorouracil, leucovorin and irinotecan 1575
    irinotecan and mitomycin-C 1729
    liposomal daunorubicin (Clinical case) 275
    paclitaxel 1133
gastric MALT lymphoma
  response to *Helicobacter pylori* 937
gastroenteropancreatic endocrine tumors
  clinical features (Review) S2: 95
  diagnosis (Review) S2: 95
  epidemiology (Review) S2: 95
gastrointestinal metastases
  in lobular breast cancer (Letter to the editor) 1765
  quality of life S3: 27
  surgical treatment S3: 27, 31
  survival S3: 31
gastrointestinal neuroendocrine tumor
  surgical treatment (Review) S2: 101
gastrointestinal tract
  as the largest endocrine organ in the body (Review) S2: 63
gelatinase A
  antimetastatic properties 389
gelatinase B
  antimetastatic properties 389
gemcitabine
  as a treatment for patients with
    advanced
      biliary tract cancer 183
      breast cancer (Short report) 1257
      non-small-cell lung cancer 1127, 1221
      pancreatic cancer 675
    cervical cancer 541
    gallbladder cancer 1403
    maximum tolerated dose 627
    myelodysplastic syndrome (Letter to the editor) 1494
    non-small-cell lung cancer 89, 1369, 1553
    ovarian cancer 1115
    pancreatic cancer 101
    small-cell lung cancer 557, 835
    urothelial cancer 946, 1417
  hand–foot syndrome 1761
  in combination with
    carboplatin 947, 1115
    cisplatin 541, 1127
    cisplatin, paclitaxel and vinorelbine 1369
    CPT-11 627
    docetaxel 89, 101, 1259
    etoposide 835
    ifosfamide 1417
    leucovorin and 5-fluorouracil 675
    paclitaxel 1553
    vinorelbine (Clinical case) 1761
  inducing a capillary leak syndrome (Clinical case) 1651
  second-line 89
  toxicity (Clinical case) 1651
  versus cisplatin and vindesine 1221
gene
  fusion
    in children with ALL (Review) 587
  involvement in tumoral progression (Review) S2: 3
  rearrangements
    in children with ALL (Review) 587
  regulation
    causing HER2 overexpression S1: 15
genetic
  pathways
    in neuroendocrine tumors (Review) S2: 3
  predisposition
    to neuroendocrine tumors (Review) S2: 3
genetics
  in oncology practice 813, 895
genito-urinary tumors
  quality of life S3: 43
geriatric assessment
  quality of life S3: 49
germ-cell tumors
  assessment of amifostine 1151
  toxicity 1151
  treatment with
    high-dose chemotherapy1151
GHRH
  analogs (Review) S2: 89
  ectopic secretion (Review) S2: 89
  in neuroendocrine tumors (Review) S2: 89
glioblastoma multiforme
  quality of life 259
  treatment with
    temozolomide 259
glioma
  diagnosis (Review) S2: 131
  levels of SSTR-2 (Review) S2: 131
gliosarcoma
  quality of life 259
  treatment with
    temozolomide 259
glycemic index
  breast cancer risks (Editorial) 1507, 1533
glycemic load
  breast cancer risks 1533
  colorectal cancer risks 173
GM-CSF
  as a treatment for patients with
    renal-cell cancer 655
  in combination with
    IL-6 655

goserelin
followed by chemoendocrine adjuvant chemotherapy 685
granulocyte colony-stimulating factor
as a treatment for patients with
breast cancer 793
in combination with
docetaxel and mitoxantrone 793
growth factors
in digestive neuroendocrine tumors (Review) S2: 13
involvement in the pathogenesis of prostate cancer (Review) S2: 145
growth hormone-releasing hormone
ectopic secretion (Review) S2: 89
in neuroendocrine tumors (Review) S2: 89
growth modulation index
in colorectal cancer 187
gynecological cancer
quality of life S3: 37

H

haematologic toxicity
of valproate 217
haematopoietic growth factors
dose escalation 471
ESMO recommendations (Special article) 1219
hand–foot syndrome
after treatment with
gemcitabine and vinorelbine (Clinical case) 1761
head and neck cancer
combined with Bloom's syndrome (Clinical case) 1015
comparison between children and adults 1157
esophageal endoscopy screening 643
in children 1157
locally advanced (Clinical case) 1015
squamous-cell cancer 1595
treatment with
cisplatin 93
cisplatin and docetaxel 199
cisplatin and raltitrexed 357
eniluracil and 5-fluorouracil 919
methotrexate 1595
nolatrexed 1595
radiation therapy (Clinical case) 1015
health protection
of European citizens (Editorial) 1033
Helicobacter pylori
response of patients with
gastric MALT lymphoma 937
hepatic arterial chemotherapy
as a treatment for patients with
colorectal cancer 599
liver metastases 321
in combination with
folinic acid and 5-fluorouracil 599
hepatic metastases
from
colorectal cancer 599
treatment with
hepatic arterial infusion, folinic acid and 5-fluorouracil 599
hepatocellular cancer
treatment with
chemotherapy (Review) 161
hepatomegaly
in patients with
diffuse liver infiltration 1005
Herceptin
as a treatment for patients with
breast cancer S1: 15, 35, 45, 49, 57, 63, 69, 89, 97
clinical response S1: 21
HER2-tests S1: 97, 101
in combination with
chemotherapy S1: 57, 69
toxicity S1: 63
treatment guidelines S1: 89
hereditary
colorectal cancer 813
microsatellite instability 813
non-polyposis colorectal cancer
microsatellite instability (Review) 151
HER2
as a predictive marker S1: 81
as a prognostic marker S1: 23, 29, 81
basic biology S1: 3
expression in patients with
breast cancer 1081, S1: 15, 57, 89, 95, 1545
mechanisms of action S1: 35
modulation of p27/Cdk2 complex formation S1: 21
monoclonal antibodies S1: 35, 81
overexpression S1: 9, 15, 21, 81
pharmacologic insights S1: 43
role in transformation S1: 9
statistical significance S1: 29
tests S1: 97, 101
therapeutic targets S1: 81
treatment guidelines S1: 89
high-dose chemotherapy
as a treatment for patients with
aggressive lymphomas 513
germ cell tumor 1151
metastatic breast cancer 69
ovarian cancer (Editorial) 583, 693
assessment of amifostine 1151
histological
differentiation
chemotherapy strategy 535
subtypes
clinical impact 311
in localized non-anaplastic nephroblastoma 311
Hodgkin's disease
ESMO minimum clinical recommendations (Special article) 1213
FDG-PET
as a predictor for survival rate 29
imaging with CT and PET 719
male gonadal dysfunction 1307
survival rate 29
transformation to high-grade B-cell lymphoma (Clinical case) 1169
treatment with
Rituximab (Clinical case) 1169
hormone-refractory

prostate cancer 847
hormone secretion
controlled by functional SSR (Review) S2: 31
hormone therapy
as a treatment for patients with
breast cancer 1539
hot flashes
treatment with
hormone replacement therapy (Review) 301
HPV testing
in cervical screening (Review) 1511
hycamtin 549
hyperinsulinemia
and breast cancer risk (Editorial) 1507
hystiocytosis
angiogenesis markers 987
role of thalidomides 987

I
IAP
as predictors of response to chemotherapy 799
in non-small-cell lung cancer 799
IdUrd
dose limitations 701
in combination with raltitrexed 701
ifosfamide
as a treatment for patients with
small-cell lung cancer 787
urothelial cancer 1417
in combination with
gemcitabine 1417
paclitaxel and carboplatin 787
IHC
HER2 tests S1: 97
immune system
exchange of information with the neuroendocrine system (Review)
S2: 125
immunohistochemistry
alkaline phosphatase (Clinical case) 1485
diffuse large B-cell lymphoma 1445
expression of
Axl 819
HER2 S1: 15
in patients with
breast cancer 525, 819, S1: 15
soft tissue sarcoma 75
metalloproteinase expression 75
overexpression of c-erbB-2 525
immunosuppression
in chronic hepatitis B infection (Clinical case) 123
indolent lymphomas
staging by PET 825
infection
association with cancer 1359
interferon
as a treatment for patients with
non-Hodgkin's lymphoma (Clinical case) 123
in combination with
vindesine (Clinical case) 483
interferon-alpha
as a treatment for patients with
melanomas (Review) 1663
neuroendocrine tumors (Review) S2: 111
pulmonary carcinoids 1383
low dose (Review) 1663
interleukin-6
as a treatment for patients with
renal-cell cancer 655
in combination with
GM-CSF 655
intestinal
epithelial cells (Review) S2: 19
non-Hodgkin's lymphoma 53
intra-arterial hepatic chemotherapy
anti-coagulant therapy (Letter to the editor) 1023
as a treatment for patients with
liver metastasis from colorectal cancer (Letter to the editor) 1023
catheter positioning (Letter to the editor) 1023
port management (Letter to the editor) 1023
intramedullary metastasis
in renal cell carcinoma (Clinical case) 1173
intravenous
administration of trastuzumab S1: 43
involved field radiation
as a treatment for patients with
nasal NK/T-cell lymphoma 349
in combination with chemotherapy 349
IORT
as a treatment for early breast cancer 1075
irinotecan
as a treatment for patients with
biliary tree cancer 501
gastric cancer 1575, 1729
metastatic colon cancer (Clinical case) 569
dose-finding 1631
in combination with
5-fluorouracil and leucovorin
mitomycin-C 1729
oxaliplatin and raltitrexed (Clinical case) 569
pharmacokinetics 1631
irinotecan hydrochloride (CPT-11)
in combination with gemcitabine 627
maximum tolerated dose 627
islet cell tumors
treatment with
dacarbazine 1139

K
Kaposi's sarcoma
complete response (Clinical case) 274
detection of tyrosinase mRNA (Letter to the editor) 1765
treatment with
liposomal daunorubicin (Clinical case) 275

L
lanreotide
as a treatment for patient with
neuroendocrine tumors (Review) S2: 111

large B-cell lymphoma
immunohistochemistry 1445
large bowel cancer
liver metastases 1711
treatment with
chemotherapy 1711
SIR-Spheres® and chemotherapy 1711
laryngeal cancer
treatment with chemoradiotherapy 343
legislation (Editorial) 145
leiomyosarcoma
in children 1163
letrozole
as a treatment for patients with
breast cancer 1527, 1539
leucopenia
chemotherapy-induced (Editorial) 1339, 1359
febrile (Editorial) 1339, 1359
in patients with
small-cell lung cancer (Editorial) 1339, 1359
reduction 1359
leucovorin
as a treatment for patients with
colorectal cancer 13, 669
gastric cancer 1575
pancreatic cancer 675
in combination with
5-fluorouracil and irinotecan 1575
5-fluorouracil and oxaliplatin 547
5-fluorouracil and gemcitabine 675
leukemia
anthracycline-induced acute cardiotoxicity 963
treatment with somatostatin (Review) S2: 125
life expectancy
as a result from follow-up examinations 1107
limited disease small-cell lung cancer
treatment with
a combination of carboplatin and etoposide 1231
hyperfractionated thoracic irradiation 1231
liposomal
daunorubicin
as a treatment for patients with
advanced non-Hodgkin's lymphoma 457
malignant pleural mesothelioma 497
doxorubicin
as a treatment for patients with
gastric Kaposi's sarcoma (Clinical case) 275
complete response (Clinical case) 275
drugs (Editorial) 433
liver
metastases
from colorectal cancer (Review) 887
from large bowel cancer 1711
surgical management (Review) 887
primary non-Hodgkin's lymphomas 1005
clinical patterns 1005
lobular cancer
gastrointestinal metastases 1765
of the breast (Clinical case) 715
rectal metastases (Clinical case) 715
long-acting repeatable octreotide
clinical management (Review) S2: 105
compared to standard subcutaneous octreotide therapy (Review) S2: 105
low grade lymphoma
treatment with liposomal daunorubicin 457
LU103793
activity in patients with malignant melanomas 509
lung adenocarcinoma
expression of nucleolar protein p120 1121
prognosis 1121
stage I 1121
lung cancer
risk assessment by radon (Review) 1341
treatment with
cisplatin and vinorelbine 59
radiotherapy and chemotherapy 59
luteinising hormone
for patients with Hodgkin's disease 1307
lymph nodes metastases
from breast cancer 1091
treatment with
radical radiation therapy 1091
lymphoma
antitumor treatment with ligands (Review) S2: 125
lymphoproliferative disorders
influence on
response to treatment 831
survival 831
posttansplant 831

M

MAID chemotherapy
as a treatment for patients with
sarcomatoid renal-cell carcinoma (Clinical case) 271
complete response (Clinical case) 271
male fertility
in patients with Hodgkin's disease 1307
malignant
ameloblastoma
treatment with
paclitaxel and carboplatin (Clinical case) 1489
metastases
detected by FDG-PET 479
FDG-PET *versus* spiral CT 479
pleural mesothelioma 497
MALT lymphoma
response to
Helibacter pylori 937
mammaglobin
as a marker for RT-PCR detection 1693
mammography
geographical disparities in self-reported use (Letter to the editor) 573
Markov model
to simulate follow-up strategies 1107
maspin
as a marker for RT-PCR detection 1693
matrix metalloproteinase inhibitors

dose optimization (Editorial) 285, 389
mechanisms of action
of anti-HER2 monoclonal antibodies S1: 35
Meckel's diverticulum
signet-ring cell adenocarcinoma (Letter to the editor) 277
medical oncology
palliative medicine (Review) 443
medullary-thyroid cancer
quality of life 1461
medroxy-progesterone acetate
as a treatment for patients with
cancer anorexia–cachexia syndrome (Review) 289
medulloblastoma
role of somatostasin (Review) S2: 131
megestrol acetate
as a treatment for patients with
cancer anorexia–cachexia syndrome (Review) 289
melanoma
activity of LU103793 509
breaking bad news 365
necrosis (Letter to the editor) 873
TNM classification (Editorial) 9
treatment with
adjuvant intereferon-alpha (Review) 1663
meningiomas
expression of somatostasin (Review) S2: 131
menopause
treatment with
hormone replacement therapy (Review) 301
Merkel cell carcinoma
somatostatin receptor scintigraphy 807
staging evaluation 807
mesothelioma
expression of
MDR 1239
P-glycoprotein 1239
resistance to chemotherapy 1239
metabolism of
5-fluorouracil 1301
gemcitabine 1553
paclitaxel 1553
metachronous cancer
esophageal endoscopy screening 643
metalloproteinase expression
in soft tissue sarcoma 75
metalloproteinase inhibitor
in soft tissue sarcoma 75
metastatic
breast cancer
prognosis 231
gastric cancer
treatment with
docetaxel and cisplatin 47
lymph node
biological markers 615
toxicity S1: 63
methotrexate
as a treatment for patients with
gastric adenocarcinoma (Clinical case) 869
head and neck cancer 1595
versus nolatrexed 1595
micrometastases
assessment by RT-PCR 39
micronutrients
role in ovarian cancer 1589
microsatellite instability
in hereditary colorectal cancer (Review) 151, 813
minimal residual disease
detection by PCR-based techniques (Review) 587
in children with ALL (Review) 587
mismatch repair
resulting in microsatellite instability (Review) 151, 813
mitomycin C
as a treatment for patients with
colorectal cancer (Letter to the editor) 575
gastric cancer 1729
in combination with
irinotecan 1729
mitoxantrone
as a treatment for patients with
breast cancer 793
chronic lymphocytic leukemia 1455
in combination with
docetaxel and G-CSF 793
fludarabine 1455
opportunistic infections 1455
MMM
as a treatment for patients with
breast cancer 685
in combination with
chemoendocrine adjuvant therapy 685
molecular biology 1445
monoamines
involvement in midgut carcinoid tumors (Review) S2: 63
monoclonal antibodies
anti-HER2 S1: 35
morphogenesis
in human prostate cancer (Review) S2: 141
mortality
in elderly patients 1467
trends 1467
moulds
causing fungal infection (Clinical case) 415
M6 subtype
of acute myeloid leukemia 451
mucositis
prevented by sucralfate 953
prevention in bone marrow transplantation 953
multidrug resistance
in human malignant mesothelioma 1239
in small-cell lung cancer 1561
relationship to chemotherapy response 1561
multiple myeloma
randomized trials 1611
refractory 991
treatment with
thalidomide and dexamethasone 991
mutation analysis

BRCA2 1699
myelodisplastic syndrome
angiogenesis markers 987
role of thalidomides 987
treatment with
gemcitabine (Letter to the editor) 1494
myeloma
angiogenesis markers 987
role of thalidomides 987

N
nasal NK/T-cell lymphoma
treatment with
chemoradiotherapy 249
CHOP and field radiation 349
nasopharyngeal carcinoma
comparison between children and adults 1157
prognosis 1157
nausea
ESMO recommendations (Special article) 1059
necrosis
in melanoma metastases (Letter to the editor) 873
neoadjuvant chemotherapy
as a treatment for patients with
breast cancer 685
cervical cancer 541
osteosarcoma 1145
prognostic factors 1145
neoplastic pathology
new biological effect of oxytocin S2: 37
nephroblastoma
clinical impact of histologic subtypes 311
neu
role in cell transformation S1: 9
neuroblastoma
role of biomarkers S2: 69
neuroendocrine
cells
as a marker for prostatic carcinoma (Review) S2: 135
differentiation
correlation with
adverse prognosis (Review) S2: 119
prognostic parameters in human prostate cancer S2: 159
in
immunolymphoproliferative diseases (Review) S2: 125
prostate cancer (Review) S2: 135, (Review) S2: 141, (Review) S2: 153
pathogenesis
in adenocarcinoma of the prostate (Review) S2: 145
phenotype
clinical significance in non-small-cell lung cancer (Review) S2: 119
treatment with subcutaneous octreotide therapy (Review) S2: 105
tumors
clinical management (Review) S2: 105
diagnosis (Review) S2: 47, (Review) 95
expression of peptide receptors (Review) S2: 63
GEP (Review) S2: 95
nuclear medicine imaging (Review) S2: 51
of the breast S2: 115
definition (Review) S2: 115
role of gut (Review) S2: 63
treatment with
radionuclide therapy 941
value of radiolabelled MIBG (Review) S2: 47
with long-acting repeatable octreotide (Review) S2: 105
neuroendocrinology
human prostate cancer S2: 27
neuroimmunomodulation
cytokine secretion (Review) S2: 19
neuropeptide Y
expression in human prostate cancer cells S2: 27
neuropeptide Y receptors
expression in human prostate cancer cells S2: 27
neuropeptides
expression in human prostate cancer (Review) S2: 145
regulating cytokine secretion of T cells (Review) S2: 19
neutropenic fever
caused by fungal infections (Clinical case) 415
neurotoxicity
in patients receiving
CPC 1411
OXAC 1411
nitrose–urea–cisplatin-based chemotherapy
associated with valproate 217
nolatrexed
as a treatment for patients with
head and neck squamous-cell cancer 1595
versus methotrexate 1595
non-Hodgkin's lymphoma
aggressive 923
bcl-2 translocation 109
clinical features 53
ESMO minimum clinical recommendations 1209
intestinal 53
of the testis 1313
prolonged neutropenia (Letter to the editor) 1493
refractory 923, 1439
relapsed 923, 1439, 1493
treatment with
anti CD20 (Letter to the editor) 1493
dexamethasone, cytarabine and oxaliplatin 1439
IVIG (Letter to the editor) 1493
liposomal daunorubicin 457
paclitaxel and topotecan 923
rituximab 109
tandem autotransplant 1749
non-seminomatous germ tumors
ESMO minimum clinical recommendations (Special article) 1215
non-small-cell lung cancer
apoptosis 799
c-erbB-4 overexpression 1127
clinical benefit response 1221
clinical evidence of neuroendocrine phenotype (Review) S2: 119
ESMO minimum clinical recommendations (Special article) 1049
hand–foot syndrome (Clinical case) 1761
managing poor performance 1659
neuroendocrine differentiation (Review) S2: 119

quality of life 1671, S3: 21
performance status 1667
prognosis 1667
response to chemotherapy 799
sequential therapy 1369
signal transduction inhibitors (Review) 739
survival rate (Review) 739, 1671
treatment with
cisplatin and vindesine 1221
cisplatin-based combination therapy 1667, 1671
cisplatin, gemcitabine, paclitaxel and vinorelbine 1369
combined modality 445
docetaxel and gemcitabine 89
docetaxel and paclitaxel (Review) 739
etoposide and topotecan 1567
gemcitabine 1221
gemcitabine and cisplatin 1127
gemcitabine and vinorelbine 1761
vinorelbine 1375
nuclear medicine imaging
of neuroendocrine tumors (Review) S2: 51
nucleolar protein p120
in patients with stage I lung adenocarcinoma 1121
predicting a poor prognosis 1121

O

ocreoscan scintigraphy
for the diagnosis of endocrine tumors (Review) S2: 95
octreotide
as a treatment for patients with
carcinoid tumors 1295
chemotherapy-induced diarrhea 227
neuroendocrine tumors 941, (Review) S2: 105, (Review) S2: 111
pulmonary carcinoids 1375
clinical management (Review) S2: 105
octreotide
as a treatment for patients with
cutaneous T-cell lymphoma (Review) S2: 125
low-grade non-Hodgkin's lymphoma (Review) S2: 125
oesophageal cancer
correlation with
drinking 975
leanness 975
smoking 975
socioeconomic circumstances 327
treatment with
epirubicin, cisplatin and raltitrexed 1407
oncogenes
in digestive neuroendocrine tumors (Review) S2: 13
oncogenetics
of medullary thyroid cancer 1461
ondansetron
followed by generalised seizures (Letter to the editor) 131
oral cancer
correlation with
drinking 331, 975
leanness 331, 975
smoking 331, 975
oral fluoropyrimidine
as a treatment for patien's with
breast cancer 1274
versus CMF 1274
oral pharyngeal cancer
socioeconomic correlates 327, 331
organ preservation
in patient with
bladder cancer 929
osteoporosis
treatment with
hormone replacement therapy 301
osteosarcoma
detection by
CT 1601
FDG-PET 479
disease-free survival 1145
FDG-PET *versus* spiral CT 479
pulmonary metastases 1601
treatment with
neoadjuvant chemotherapy 1145
ovarian cancer
disease management (Review) 1195
ESMO minimum clinical recommendations (Special article) 1205
hereditary 1699
micronutrients 1589
relapsed 1705
relation with female hormones 337
treatment with
carboplatin and gemcitabine 1115
cisplatin and etoposide 1705
high-dose chemotherapy (Editorial) 583, 693
platinum drugs 1195
ovary cancer
treatment with high-dose chemotherapy 693
overexpression
in B-cell chronic lymphocytic leukemia 981
of the p73 gene 981
OXAC
as a treatment for patients with
ovarian cancer 1411
neurotoxicity 1411
oxaliplatin
as a treatment for patients with
breast cancer 179
colorectal cancer 187, 519, (Clinical case) 569, 669, 709, 1737
dose limitations 1737
metastatic colon cancer 569
non-Hodgkin's lymphoma 1439
continuous infusion (Letter to the editor) 1653
idiosyncratic reaction (Letter to the editor) 1653
in combination with
capecitabine 1737
dexamethasone and cytarabine 1439
5-fluorouracil 187, 519
5-fluorouracil and leucovorin 669
irinotecan and raltitrexed (Clinical case) 569
raltitrexed 709
idiosyncratic reaction (Letter to the editor) 132, (Letter to the editor) 874

oxaliplatin-related peripheral sensitive neuropathy
treatment with amifostine (Letter to the editor) 421
oxytocin
biological relevance S2: 37
role in neoplastic pathology S2: 37
oxytocin receptors
biological relevance S2: 37

P
paclitaxel
as a treatment for patients with
breast cancer (Review) 593, 605, 1067, S1: 69, 1545
gastric cancer 1133
malignant ameloblastoma (Clinical case) 1489
metastatic breast cancer 69
non-Hodgkin's lymphoma 923
non-small-cell lung cancer 193, (Review) 739, 787, 1369, 1553
small-cell lung cancer 463
solid tumors 549, 1743
hypersensitivity reactions 1133
in combination with
capecitabine 605
carboplatin 193, (Clinical case) 1489
carboplatin and topotecan 549
cisplatin and etoposide 463
cisplatin, gemcitabine and vinorelbine 1369
docetaxel, epirubicin and trastuzumab S1: 69
docetaxel (Review) 739, 1743
doxorubicin 1067
epirubicin 69, (Review) 593
ifosfamide and carboplatin 787
topotecan 923
trastuzumab 1545
vinorelbine 85
PALA
as a treatment for patients with
gastrointestinal cancer 1581
palliative chemotherapy
changes in serum PSA 773
for patients with
metastatic colorectal cancer 221
prostate cancer 773
palliative first-line treatment
for patients with
colorectal cancer 1721
palliative medicine
medical oncology (Review) 443
pamidronate
as a treatment for patients with
metastatic bone disease 1433
in combination with
clodronate 1433
pancreatic cancer
islet cell tumors 1139
occurrence of carcinomatous meningitis (Clinical case) 1757
treatment with
anthracycline 1399
CAELYX 1399
chemoradiation 681
CYP2B1 /cyclophosphamide 379
dacarbazine 1139
leucovorin, 5-fluorouracil and gemcitabine 675
tumor regression 379
pancreatic metastasis
of alveolar soft-part sarcoma 865
pancreatoduodenectomy
as a treatment for patients with
alveolar soft-part sarcoma (Clinical case) 865
papillary cancer
in a man (Clinical case) 563
of the peritoneum (Clinical case) 563
pathology (Clinical case) 563
paraganglioma
biomarkers S2: 69
clinical significance of blood chromogranin A S2: 69
paraneoplastic pemphigus
as the presentation of CLL (Clinical case) 115
patient
preferences 365
patient-physician relationship 365
PCR
for children with ALL (Review) 587
HER2 tests S1: 97
predicting disease recurrence 39
quantitative 39
to detect B-cell tumor-specific molecular fingerprint 1479
to detect MRD (Review) 587
pediatric tumors 1157, 1163
pegylated liposome
cisplatin 493
peptide hormones
in gut neuroendocrine tumors (Review) S2: 63
peptide imaging
of neuroendocrine tumors S1: 51
peripheral blood
breast carcinoma cells 39
peripheral blood progenitor cell mobilization
in patients with
relapsed indolent lymphoproliferative disorders 1455
peripheral blood stem-cell transplantation
as a treatment for patients with
ovarian cancer 693
in combination with
high-dose chemotherapy 693
peripheral neuroectodermal tumors
biomarkers S2: 69
clinical significance of blood chromogranin A S2: 69
peritoneal carcinomatosis
complete response (Clinical case) 275
gastric Kaposi's sarcoma (Clinical case) 275
treatment with
liposomal daunorubicin (Clinical case) 275
peritoneal neoplasm
in a man (Clinical case) 563
PET
value for localised CUP 1605
PETACC 13
p-53

as a treatment for patients with
pancreatic cancer 379
enhancing tumour regression 379
similarity with the p73 gene 981
thymidylate synthase 779
P-glycoprotein
in small-cell lung cancer 1561
pharmacokinetics (Clinical case) 119, 605, 1289, 1301, 1631, 1643, S1: 43, 49
pharyngeal cancer
correlation with drinking 331
correlation with leanness 331
correlation with smoking 331
phase I trials
dose finding 1631
of patients with
advanced
breast cancer 1097, 1683
head and neck cancer 357
small-cell lung cancer 787
head and neck cancer 493
metastatic
breast cancer 909, S1: 49, 69
colorectal cancer 321
non-Hodgkin's lymphoma 661
renal cell cancer 655
solid tumors 549, 1289
to evaluate the efficacy of
BBR 2778 661
cisplatin 493
cisplatin and raltitrexed 357
docetaxel and epirubicin 1097
docetaxel and vinorelbine 909
E7070 1289
5-fluorouracil and folinic acid 321
gemcitabine and CPT-11 627
GM-CSF and IL-6 655
ifosfamide, paclitaxel and carboplatin 787
irinotecan 1631
raltitrexed and IdUrd 701
topotecan, carboplatin and paclitaxel 549
trastuzumab S1: 49, 69
vinorelbine 1683
phase II trials
of patients with
advanced
breast cancer 1259
head and neck cancer 919
anal cancer 397
biliary tree cancer 501
breast cancer 1274
gallbladder cancer 1403
gastric cancer 1133
head and neck cancer 493, 919
malignant melanomas 509
malignant pleural mesothelioma 497
metastatic
breast cancer S1: 49, 69
pancreatic cancer 1139
prostate cancer 847, 1273
small-cell lung cancer 835
soft tissue sarcoma 1281
to evaluate the efficacy of
capecitabine 1274
cisplatin 493
cisplatin and 5-fluorouracil 397
CMF 1274
dacarbazine 1139
docetaxel 1273, 1281
docetaxel and gemcitabine 1259
5-fluorouracil and eniluracil 919
gemcitabine 1403
gemcitabine and etoposide 835
irinotecan 501
liposomal daunorubicin 497
LU103793 509
paclitaxel 1133
trastuzumab S1: 49, 69
vinorelbine 847
phase III trial
of patients with
advanced non-small-cell lung cancer 1221
metastatic breast cancer S1: 69
to evaluate the efficacy of
gemcitabine *versus* cisplatin–vindesine 1221
trastuzumab S1: 69
plasma exchange (Clinical case) 123
platinum drugs
as a treatment for patients with
ovarian cancer (Review) 1195
platinum resistance
in patients with ovarian cancer (Review) 1195
pleura
expressed in human malignant mesothelioma 1239
PNET
expression of somatostatin (Review) S2: 131
polymorphisms
of metabolizing enzymes (Review) 1515
positron emission tomography
compared to CT 719
imaging Hodgkin's disease 719
staging non-Hodgkin's lymphoma 825
with fluorine-18 fluorodeoxyglucose 825
posterior leukoencephalopathy syndrome
following CHOP chemotherapy (Clinical case) 1327
postmenopausal
breast cancer patients 1527
post-transplant lymphoproliferative disorders
influence on
response to treatment 831
survival 831
predictive markers
HER2 1081, S1: 23,. 29, 81, 89, 101
topo-isomerase IIα 1081
preoperative chemotherapy
as a treatment for
patients with localized non-anaplastic nephroblastoma 311
postmenopausal women (Editorial) 1505, 1527

clinical impact 311
with
letrozole 1527
prevention
of lung cancer (Review) 1341
primary
breast cancer
ESMO minimum clinical recommendations (Special article) 1047
non-Hodgkin's lymphoma 53
tumors
biological markers 615
relevance of oxytocin S2: 37
prognosis
after treatment with
cisplatin-based combination therapy 1667
neoadjuvant chemotherapy 1145
correlation with
changes in serum PSA 773
palliative response 773
for children with head and neck cancer 1157
for patients with
breast cancer 525, S1: 23
head and neck cancer 1157
metastatic breast cancer 81, 231
non-small-cell lung cancer 1667, (Review) S2: 119
osteosarcoma 1145
prostate cancer 773
soft tissue sarcoma 75
prognostic
factors
c-erbB-2 oncoprotein overexpression 525
cytokine serum levels 1423
epidermal growth factor receptor expression 841
for children with
ALL (Review) 587
for patients with
acute myeloid leukemia 451
chronic lymphocytic leukemia 621
localized non-anaplastic nephroblastoma 311
Hodgkin's lymphoma 1307
osteosarcoma 1145
HER2 S1: 23, 29, 81, 89, 101
histological subtypes 311
metalloproteinase expression 75
MRD detection (Review) 587
neuroendocrine features
neuroendocrine phenotype in NSCLC (Review) S2: 119
relation with neuroendocrine features S2: 159
response to chemotherapy 231
serum levels 621
progression-free interval
in patient with
chronic lymphocytic leukemia 621
prostate cancer
androgen-independent 847, 1273
changes in serum PSA 773
clinical value of circulating chromogranin A (Review) S2: 153
expression of neuropeptide Y S2: 27
hormone refractory 633, 773, 847
neuroendocrine differentiation (Review) S2: 135, (Review) S2: 141, (Review) S2: 145
neuroendocrine pathogenesis (Review) S2: 145
palliative response 773
relation
between neuroendocrine factors and prognostic parameters S2: 159
with tobacco smoking (Editorial) 733, 761
survival 773
treatment with
docetaxel 1273
docetaxel, estramustine and hydrocortisone 633
vinorelbine 847
prostate specific antigen
correlation with CgA levels (Review) S2: 153
efficacy of vinorelbine 847
protracted continuous infusion
as a treatment for patients with
advanced colorectal cancer 519
PSA-defined response
in patients with prostate cancer 773
relation with
palliative response 773
survival rate 773
p73
overexpression 981
role in B-cell chronic lymphocytic leukemia 981
p27
modulation through 4D5-mediated inhibition of HER2 receptor signaling S1: 21
pulmonary metastases
detected by FDG-PET 479
FDG-PET *versus* spiral CT 479
treatment with
interferon-alpha 1383
octreotide 1383
pulmonary toxicity
induced by gemcitabine (Clinical case) 1651

Q

QC12
bioavailability 245
quality assessment
of therapeutic innovations in multiple myeloma 1611
quality of life
after surgical treatment S3: 15, 27
definition S3: 1, 3
drop out problems S3: 11
end point S3: 3
evaluating problems S3: 11
geriatric assessment S3: 49
health-related S3: 7
in elderly patients S3: 49
in patients
and partners 633
receiving chemotherapy 259
with
breast cancer 1461, S3: 15
gastrointestinal tumors S3: 27, 31

genito-urinary tumors S3: 43
gliobastoma multiforme 259
gynecological cancer S3: 37
hormone refractory prostate cancer 633
lung cancer S3: 21
medullary thyroid cancer 1461
unresectable non-small-cell lung cancer 1671
quantitative PCR
predicting disease recurrence 39
versus RT-PCR 39
quercetin
bioavailability 245
questionnaire
to evaluate genetic risk and impaired quality of life 1461

R

radiation sensitization
in patients with pancreatic cancer 681
radiation therapy
as a treatment for patients with
anal cancer 397
breast cancer 1091
nasal NK/T-cell lymphoma 349
renal cell carcinoma (Clinical case) 1173
diagnosis of ISCM (Clinical case) 1173
in combination with chemotherapy 397
versus chemotherapy 1091
radionuclides
value in diagnosis and management of neuroendocrine tumors S2: 47
radionuclide imaging
for tumor detection 825, S2: 41
role of somatostatin S2: 41
radionuclide therapy
as a treatment for patients with
neuroendocrine tumors 941
importance of tumor detection S2: 41
radiotherapy
after breast conserving surgery 373, 997
as a treatment for patients with
brain metastases 59
breast cancer 373, 997
non-small-cell lung cancer 59
small breast carcinoma 997
dose-intensity 373
in combination with
chemotherapy 59, 373
radon
as a risk for lung cancer (Review) 1341
raltitrexed
as a treatment for patients with
colorectal cancer (Clinical case) 569, 709
gastric cancer 1407
head and neck cancer 357
oesophageal cancer 1407
rectal cancer 1023
in combination with
cisplatin 357
cisplatin and epirubicin 1407
IdUr 701
irinotecan and oxaliplatin (Clinical case) 569
oxaliplatin 709
randomised clinical trials
critical appraisal 1611
evidence-based medicine 1611
innovations 1611
quality assessment 1611
to evaluate therapy for
breast cancer 1075
cancer anorexia-cachexia syndrome (Review) 289
head and neck cancer 1595
multiple myeloma 1611
small-cell lung cancer 463
to evaluate the efficacy of
cisplatin, etoposide and paclitaxel 463
nolatrexed *versus* methotrexate 1595
Targit 1075
REAL classification
usefulness 853
receptor overexpression
in cell transformation S1: 9
rectal cancer
dietary glycemic load 173
from lobular cancer of the breast (Clinical case) 715
treatment with
chemoradiotherapy (Review) 1039
recurrent
disease
follow-up examinations 1107
life expectancy 1107
high-grade glioma 255
relapses
in patient with
localized non-anaplastic nephroblastoma 311
renal cell cancer
intramedullary spinal cord metastasis (Clinical case) 1173
reproduction
relation with ovarian cancer 337
research end point
quality of life S3: 3
resection
as a treatment for patients with
hepatocellular cancer (Review) 161
residual disease
in patients with
breast cancer 1693
RT-PCR detection 1693
resistant
small-cell lung cancer 557
response
to preoperative chemotherapy 311
to chemotherapy
predicted by IAP 799
retreatment
of patients with the same chemotherapy (Review) 23
retroperitoneum
in diffuse large B-cell lymphoma 1445
rhinocerebral zygomycosis
in patients with acute lymphoblastic leukemia (Clinical case) 415

risk factors
radon (Review) 1341
female hormones 337
socio-economic correlates 327
Rituximab
after transformation to high-grade B-cell lymphoma (Clinical case) 1169
as a treatment for patients with
follicular lymphoma S1: 23
mantle-cell lymphoma S1: 117, 123
multiple myeloma S1: 107
non-Hodgkin's lymphoma 109, (Clinical case) 1169
bcl-2 translocation 109
remission (Clinical case) 1169
roxithromycin
as a treatment for patients with
small-cell lung cancer (Editorial) 1339, 1359
in combination with
ciprofloxacin 1359
reducing febrile leucopenia 1359
RT-PCR
used to detect
breast carcinoma cells in peripheral blood 39
versus quantitative PCR 39

S
salvage therapy
as a treatment for patients with
breast cancer 1265
non-Hodgkin's lymphoma 1439
urothelial cancer 1417
sarcoidosis
immunohistochemical staining pattern (Clinical case) 1485
sarcomatoid renal-cell carcinoma
complete response (Clinical case) 271
treatment with
doxorubicin (Clinical case) 271
MAID chemotherapy (Clinical case) 271
scientific committees
representation (Letter to the editor) 277
second line treatment
for patients with
colorectal cancer 709
ovarian cancer 1115
with
oxaliplatin and raltitrexed 709
second
malignancies
cytostatic drug therapy 1619
primary malignancies
life expectancy 1107
secondary metastatic resection
as a treatment for patients with
colorectal cancer 1721
sentinel lymph node biopsy
following breast conserving therapy (Letter to the editor) 723
in patients with breast cancer (Letter to the editor) 723
serum
levels
as a prognostic instrument 621
thymidine kinase levels
as a prognostic factor 621
signal transduction
in non-small-cell lung cancer (Review) 739
role of HER2 S1: 35
signet-ring cell adenocarcinoma
in Meckel's diverticulum (Letter to the editor) 277
in gastric adenocarcinoma (Clinical case) 869
SIR-Spheres
as a treatment for
large bowel cancer 1711
SIRT
as a treatment for
large bowel cancer 1711
small breast carcinoma
radiotherapy 997
small-cell carcinoma
of the esophagus (Clinical case) 1321
treatment with
chemotherapy (Clinical case) 1321
small-cell lung cancer
as a type of ectopic ACTH syndrome S2: 83
chemotherapy response 1561
ESMO minimum clinical recommendations (Special article) 1051
extensive disease 835
in elderly patients 957
multidrug resistance 1561
quality of life S3: 21
reduction of chemotherapy-induced febrile leucopenia (Editorial) 1339, 1359
resistant 557
salvage treatment 193
sustaining Cushing's syndrome S2: 83
treatment with
carboplatin and cisplatin 647
carboplatin and etoposide 957
ciprofloxacin and roxithromycin (Editorial) 1339, 1359
cisplatin (Editorial) 585
cisplatin, etoposide and paclitaxel 463
etoposide and topotecan 1567
gemcitabine 557
gemcitabine and etoposide 835
hyperfractionated thoracic irradiation 1231
ifosfamide, paclitaxel and carboplatin 787
paclitaxel and carboplatin 193
smoking
correlation with
oesophageal cancer 975
oral cancer 331, 975
pharyngeal cancer 331
prostate cancer (Editorial) 733, 761
socio-economic factors
relation with oesophageal cancer 327
soft tissue sarcoma
anthracycline-resistant 1281
blood cell count 1423
cytokine serum levels 1423
ifosfamide-resistant 1281

in children 1163
metalloproteinase expression 75
prognosis 75, 1423
treatment with
docetaxel 1281
solid tumors
autologous stem-cell transplantation (Letter to the editor) 131
treatment with
E7070 1289
somatostatin
controling symptoms in patients with neuroendocrine tumors (Review) S2: 105
expressed in neuroendocrine tumors (Review) S2: 131
role in radionuclide imaging S2: 41
receptor scintigraphy 807
receptor subtypes
expression in human tumors (Review) S2: 31
role in radionuclide imaging S2: 41
scintigraphy
of Merkel cell carcinomas 807
of neuroendocrine tumors (Review) S2: 51, (Review) 95
somatostatin analogs
as a treatment for patients with
lymphoproliferative diseases (Review) S2: 125
neuroendocrine tumors 941, (Review) S2: 111
somatostatin receptors
as a means for tumor localization (Review) S2: 125, (Review) S2: 131
S-phase fraction
in patient with
colorectal cancer 239
tumor resistance 239
sphincter preservation
through chemoradiotherapy (Review) 1039
spinal cord tumors
in renal cell carcinoma (Clinical case) 1173
squamous-cell cancer
of head and neck 199, 919
treatment with
a combination of
docetaxel and cisplatin 199
eniluracil and 5-flourouracil 919
staging
of Hodgkin's lymphoma (Clinical case) 719
of Merkel cell carcinomas 807
of non-Hodgkin's lymphoma 825
Starling's forces of capillary hemodynamics
pathogenesis of malignant ascites (Review) 1353
statistics S1: 29
stem-cell transplantation
as a treatment for patients with
chronic lymphocytic leukemia S1: 49
follicular lymphoma S1: 23
Hodgkin's lymphoma 867
prevention of mucositis 953
role of sucralfate 953
stomatitis
correlation with chronic lymphocytic leukemia (Clinical case) 115
streptozocin
as a treatment for patients with
neuroendocrine tumors (Review) S2: 111
subcutaneous
administration of trastuzumab S1: 45
sucralfate
role in the prevention of mucositis 953
sulfonamide
as a treatment for patients with
solid tumors 1289
supraclavicular lymph-nodes metastases
treatment with
radiotherapy 1091
surgery
as a treatment for patient with
breast cancer S3: 15
chondrosarcoma of bone 859
gastrointestinal neuroendocrine tumors (Review) S2: 101, S3: 27
hepatic metastases from colorectal malignancies (Review) 887
margins 859
postoperative functions 859
quality of life S3: 15, 27
survival rate
disease free 29
of patients with
aggressive lymphomas 513
carcinoid disease 1295
Hodgkin's lymphoma 29
metastatic breast cancer 81
non-small-cell lung cancer (Review) 739
small-cell lung cancer 835
unresectable non-small-cell lung cancer 1671
predicted by FDG-PET 29
quality of life S3: 1
sweet gland tumors
treatment with
docetaxel (Clinical case) 411
synaptophysin
correlation with ultrastructural evidence of NE differentiation (Review) S2: 119
syndromes
predisposing endocrine cell proliferation (Review) S2: 3

T

tamoxifen
HER2 tests S1: 101
prognostic factors S1: 101
tandem autotransplant
as a treatment for patient with
non-Hodgkin's lymphoma 1749
targeted intra-operative radiotherapy
as a treatment for patients with
breast cancer 1075
targeted radiotherapy
role of SSR (Review) S2: 31
Targit
as a treatment for patients with
breast cancer 1075
taxane-refractory
advanced breast cancer 1255
Taxol

as a treatment for patients with
breast cancer 605
solid tumors 549
Taxotere
as a treatment for patients with
breast cancer 353, 1393
eccrine porocarcinoma (Clinical case) 411
T-cell
cytokine secretion (Review) S2: 19
regulated by neuropeptides (Review) S2: 19
rich/histiocyte-rich BCL 853
technetium-99m methoxyisobutylisonitrile
chest imaging for small-cell lung cancer 1561
temozolomide
as a treatment for patients with
brain tumors 249, 255, 259
quality of life 259
testicular cancer
PET (Clinical case) 1485
PLAP (Clinical case) 1485
prognosis 487
role of sarcoidosis (Clinical case) 1485
testicular seminoma
ESMO minimum clinical recommendations (Special article) 1217
testis
Non-Hodgkin's lymphoma 1313
thalidomide
angiogenesis markers 987
as a treatment for patients with
refractory multiple myeloma 991
in combination with
dexamethasone 991
role of thalidomides 987
revitalization (Editorial) 885
therapeutic management
value of PET 1605
therapeutic targets
for HER2 tumor types S1: 81
therapy response prediction
in patients with breast cancer 525
of c-erbB-2 oncoprotein overexpression 525
thymidine phosphorylase
upregulated by paclitaxel 605
thoracic radiotherapy
as a treatment for patient with
limited disease small-cell lung cancer 1231
to detect pulmonary metastases 479
versus FDG-PET 479
versus treatment with carboplatin and etoposide 1231
thymidylate synthase
expressed in patients with colorectal cancer 209, 239
inhibited by 5-fluorouracil 209
tumor resistance 239
Thymitaq
as a treatment for patients with
head and neck cancer 1595
versus methotrexate 1595
tomography
in suspected testicular cancer relapse (Clinical case) 1485
role of sarcoidosis (Clinical case) 1485
topoisomerase inhibitors
as a treatment for patients with
lung cancer 1567
topoisomerase I
dose-finding 1631
pharmacokinetics 1631
topoisomerase IIα
as a treatment for patients with
breast cancer 1081
inhibited by dexrazoxane 405
topotecan
as a treatment for patients with
lung cancer 1567
non-Hodgkin's lymphoma 923
solid tumors 549
in combination with
carboplatin and paclitaxel 549
etoposide 1567
paclitaxel 923
infusion
effect on cerebrospinal fluid (Clinical case) 119
toxicity
assessment of amifostine 1151
chemotherapy-induced 1151
in patients with
germ cell tumors 1151
head and neck cancer 493
metastatic breast cancer S1: 63
non-small-cell lung cancer 1553
of
cisplatin 493
5-fluorouracil 1301
gemcitabine 1553
paclitaxel 1553
trastuzumab S1: 63
transitional cell carcinoma
treatment with
gemcitabine and CPT-11 627
transplantation
as a treatment for patients with
hepatocellular cancer (Review) 161
posttransplant lymphoproliferative disorders 831
transporter proteins
involvement in the clearance of anticancer agents (Review) 1515
trastuzumab
administration S1: 45
as a treatment for patient with
breast cancer S1: 15, 35, 45, 49, 57, 69, 89, 95, 1545
clinical response S1: 21
clinical trials S1: 49, 69
future directions S1: 75
HER2 tests S1: 97, 101
in combination with
chemotherapy S1: 57, 63, 69
epirubicin S1: 69
paclitaxel S1: 69, 1545
pharmacologic insights S1: 43
survival rate S1: 57

tolerability S1: 63, 101
treatment guidelines S1: 89
truth telling
to patients 365
tumor
deregulation of genetic pathways (Review) S2: 3
expression of somatostatin receptor subtype (Review) S2: 31
association with SIADH (Clinical case) 1061
in patients with small-cell lung cancer (Clinical case) 1061
response
after treatment with
temozolomide 259
in brain cancer patients 259
specific molecular fingerprint 1479
staging
in children and adults with head and neck cancer 1157
suppresor gene
in digestive neuroendocrine tumors (Review) S2: 13
in digestive neuroendocrine tumors (Review) S2: 13
tumorigenesis
in hereditary non-polyposis colorectal cancer (Review) 151
tyrosine kinase activity
role of HER2 in signal transduction S1: 9
tyrosinase mRNA
in tumor tissue microdissections (Letter to the editor) 1765

U

unknown primary cancer
treatment with
cisplatin, continuous infusion 5-fluorouracil and etoposide 535
urothelial cancer
treatment with
gemcitabine and carboplatin 947
gemcitabine and ifosfamide 1417
salvage chemotherapy 1417

V

valproate
associated with nitrose–urea–cisplatin-based chemotherapy 217
vascular
endothelial growth factor
in patient with
colorectal cancer 239
interference as a therapeutic target (Review) 1353
tumor resistance 239
vinca alkaloid
bioavailability 1643
vinorelbine
as a treatment for patients with
advanced
breast cancer 95, 1677, 1683
non-small-cell lung cancer 59
brain metastases 59
breast cancer 909, 1061
endometrial cancer 767
non-small-cell lung cancer 1369, 1375
solid tumors 1643
dose limitation 1683
feasibility 1677
hand–foot syndrome (Clinical case) 1761
in combination with
cisplatin 59, 767
cisplatin and 5-fluorouracil 95
ciplatin, paclitaxel and gemcitabine 1369
docetaxel 909, 1061
gemcitabine (Clinical case) 1761
intravenous 1375
oral 1643, 1677, 1683
bioavailibility 1643
versus intravenous 1375
safety profile 1677
vomiting
ESMO recommendations (Special article) 1059

Z

Zollinger–Ellison syndrome
gastrin-mediated (Review) S2: 95

Index of authors Volume 12 (2001)

A

Aapro M 435
Abel U 311
Abrahamsson P-A S2: 1, S2: 145
Abratt RP 277
Achten R 853
Adamo V 1091
Adamou A 1545
Adams JR 1611
Adams R 681
Adenis A 1643
Aderka D 563
Adjei AA 389, 627, 701
Advani SH 1493
Aebi S 583, 981, 1026, 1654
Aerts J 39
Agelaki S 101, 193, 793
Agelidou M 463
Agnanti N 715
Agresti R S1: 15
Ahlman H S2: 63
Ahn YC 349
Ahrens S 1619
Ahumada M 1403
Ajarim DS 53
Akbulut H 1011
Al Rabih W 53
Al-Foudeh MO 53
Alaggio R 1163
Albanell J S1: 35
Alberts SR 389, 627
Alexopoulos A 793
Ali A S2: 83
Alietti A 987
Alkuzweny B 109
Allegra CJ 123, 1581
Allegrini G 1301
Allione B 203
Almici C 203
Alonso C 1699
Altermatt HJ 819
Alvegard TA 1601
Amadori D 289, 443, 1067
Amann G 1281
Ames MM 701
Amistà P 255
Anagnostopoulos N 991
Anastasopoulou A 853
Anderson D 245
Anderson J 831, 1711
André S 525
André T 675
Andrès E 865
Andres A-C 819
Andres R 1061
Androulakis N 193
Angelberger P S2: 41
Angelelli B 519
Angeli A S2: 1, S2: 73, S2: 83, S2: 153, S2: 159
Anti M 813
Aparicio J 487
Appfelstaedt J 1527
Aravantinos G 101, 1417
Arbuck SG 1067
Archer VR 575
Ardizzoni A 1359
Armitage J 831
Arnold A S1: 43
Arranz Arija JA 487
Arrigoni G 1693
Ascani S 1445
Aschelter AM 179
Ascierto PA 1766
Asselain B 231
Astolfi M 1693
Atherton PJ 389, 627, 701
Atkin WS 151
Attems Y 1281
Augustin LSA 173, 1533
Aulitzky WE 1619
Ausili-Cefaro G S3: 49
Austoker J 1189
Avallone A 199
Avril MF 807
Avril N 719
Awada A 1757
Ayoub J-P S1: 43
Azli N 909
Azoulay D 1005

B

Baatenburg de Jong RJ 357
Bacci G 1145, 1601
Bachelot A S2: 79
Backus HHJ 209, 779
Bacoyiannis C 249
Baek C-H 349
Baena M 1699
Bafaloukos D 249, 1417, 1545
Baiget M 1699
Bajetta E S2: 69
Baldelli AM 239
Balladelli A 75
Ballatori E S3: 11, S3: 37
Balmaña J 1699
Balmes P 59
Balosso J 675
Baltayiannis G 715
Bamias A 249, 715
Bangalore N 271
Bania E 463
Barbarisi A S3: 27
Barbui T 430
Bardou VJ 513
Barlow C 1327
Barrett A 422
Barthier S 1265
Barton CM 1255
Baselga J S1: 35, S1: 49
Baskaynak G 981
Basso U 255
Battistoni F 132
Baudin E S2: 79
Bauer J 353
Baum M 1075
Baum U 1721
Beauduin M 847, 1081
Beaujean F 1749
Beckendorf V 1313
Becker D 1721
Beckert B 599
Beeney LJ 365
Beer TM 1273
Beguin Y 825
Beijnen JH 787
Belhabri A 451
Belhadj K 1749
Bell D 1247
Bell R S1: 69
Bellina M S2: 159
Belloc J 869
Belpomme D 1595
Benassi MS 75
Bendandi M 1479
Bengala C 69
Benhamou E 953
Bennett CL 1611
Bennouna J 59
Benson AB 1575
Beny A 227
Berardi R 277
Berclaz G 819
Berdel WE 415
Beretta GD 284, S3: 31
Bergaglio M 505, 1097
Berghmans T 585
Berlin J 1575
Bernareggi A 661
Bernatik T 1721
Bernstein J 457
Berruti A S2: 73, S2: 153, S2: 159
Bertelli G 505
Bertetto O S3: 43
Berti F 255
Bertoglio S 505

Bertolini F 987
Bertoni F 75, 1145
Bertucci D 1743
Bettini R S2: 101
Beuvink I S1: 21
Beuzeboc P 231, S1: 81
Beyer J 1151
Beykirch M 599
Bhargava P 271
Bidart JM S2: 79
Bidoli E 1589
Bielack S 479
Bierman P 831
Biesma B 1359
Biganzoli L 1496
Bighin C 505
Biglietto M 199
Billingham LJ 1671
Biron P 1313
Bischoff J 1393
Bismuth H 1005
Bisogno G 1163
Bissery M-C 909
Blair S 89
Blaise D 513
Blandy C 1461
Blanke CD 1575
Blatter J 835
Blay J-Y 275
Blewitt L 575
Bloemena E 209, 779
Blohmer JU 1115
Blum JL 605, 1247
Boccardo F 1023
Bocci G 1301
Bogdanić V S1: 95
Bohuslavizki KH 29
Boige V 869
Bokemeyer C 435
Boku N 1133
Bollito E S2: 153, S2: 159
Bombardieri E S2: 51, S2: 69
Bonadonna S S2: 89
Boneterre ME 509
Bonetti A 187
Bonkhoff H S2: 141
Bonnefoi H 1658
Bonneterre J 1255, 1683
Bontke N 435
Boot H 1765
Borchmann P 661
Borel C 535, 643
Borg-Olivier O 909
Borgs M 1527
Börner AR 1605
Borner M 353
Borsellino N 767
Bosetti C 327
Bosquée L 835
Bosset JF 1321
Boswell W 457
Botti S 1479
Bouabdallah R 513
Bouchardy C 573, 1188
Boulefdaoui B 1439
Boulez J 275
Bourg V 217
Bovio S S2: 83
Boyle P 173, 761, 1467
Bracarda S S3: 43
Bracci R 277
Bracko M 267
Brada M 259
Braess J 599
Brandes AA 255
Brandes I 953
Bravo-Marques JM 259
Bredenfeld H 1307
Bregni M 1693
Breton JL 59, 957, 1677
Breuer K 1307
Brewster DH 145
Breza J 847
Briassoulis E 1231
Briccoli A 1601
Brienza S 179, 187
Brisgand D 1667
Brodowicz T 1281
Bronner G 643
Brooks A 947
Browman G 919
Brown M 1067
Brueckl WM 1721
Bruner J 259
Bruns J 859
Bruzzi P 1331
Bruzzone M 1023
Buchanan LA 457
Buchert R 29
Buchholz E 1359
Büchner T 415
Buclon M 693
Budišić Z S1: 95
Bueso P 1061
Bugat R 847, 1019
Buhl Jensen P 405
Bühler H S1: 97
Bukowski RM 655
Bumann D 29
Bunn Jr PA 1339
Burattin A S2: 89
Burch PA 627, 701
Burger H-U 1247
Burghouts J 1359
Burlini A 987
Burton M 1711
Bussolati G S2: 37, S2: 115
Butow PN 365

C
Cabanillas F 923
Cacciola E 621
Cajot J-F 981
Calbó J 379
Calender A S2: 3
Calvert H 509
Çam R 1011
Camboni GM 661
Campana D S2: 95
Campiglio M S1: 15
Campone M 909, 1289
Campos B 1699
Canavese G 373
Candoni A 203
Cantore M 1023
Cantrell CL 549
Capelli P S2: 101
Caponigro F 199
Cappia S S2: 159
Cara S 23
Carbone A 853, 1589
Carbone PP 1139
Cardoso F 615, 1757
Caristi N 1091
Carles J 487
Carli M 1163
Carlini P 1539
Carman L 89, 1259
Carnaghi C S2: 119
Carpi A 1737
Carrara S 813
Carrió M 379
Casali A 1539
Casalini P S1: 15
Casanova M 1157, 1163
Cascalló M 379
Cascinu S 239, 1091, S3: 31
Cassoni P S2: 37, S2: 115
Castagna L 953
Castello G 1766
Castera D 1411
Castiglione-Gertsch M 583
Catalano G 239
Catalano V 239
Catania C 95
Catania C 1651
Cattan S 675
Caty A 847
Cavalla P S2: 131
Cavallari M 373
Cavalli F 151
Çay F 1011
Cecchetto G 1163
Cefalo G 1157
Cellerino R 277
Cerri R 203
Cerundolo V 1182
Cetto GL 187

Chabannon C 513
Chabuk C 1581
Chacón JI 1369
Chanona J 541
Chapuis B 1032
Charrin C 451
Chassagne C 1313
Chau N 1461
Chaudri-Ross HA 1527
Chauvin F 693
Chayvialle JA S2: 3
Chelghoum Y 451
Chen AP 1581
Cherubini R 1737
Chevalier B 1683
Chevreau Ch 1313
Chiaffarino F 337
Chichmanian RM 217
Chiesa F 75
Chin K 1729
Chinet-Charrot P 1313
Chiti A S2: 51
Chiusa L S2: 115
Chollet Ph 1411
Chopin D 847
Chott A 937
Chowers Y S2: 19
Christakis I 991
Christiaens M-R 39
Christodoulou Ch 249, 1545
Cinieri S 987
Cionini L 1301
Cirkel DT 1255
Clarke R 919
Clausen M 29
Clavio M 203
Clendeninn N 1595
Closon-Dejardin M-T 1081
Cnaan A 1139
Coco C 813
Cocorocchio E 987
Coëtmeur D 957
Cogliandolo S 813
Cognetti F 1097, 1539, 1737
Colao A S2: 125
Colborn D 89, 1259
Coleman MP 145
Coleman RE 1433
Colin P 675
Colita A 451
Collao Lamb C 723
Colleoni M 95, 724
Colombo N 967
Colozza M S3: 15
Comella G 199
Comella P 199
Conroy T 397
Conte PF 69, 1301
Contedevolx B 1461
Conti E 331, 337, 1589
Cook JE 245
Cooke A 919
Cooke T S1: 23
Coombes RC 685
Corinaldesi R S2: 95
Corleto VD S2: 13
Corradini P 1693
Corry J 1015
Corsini C 987
Cortesi E 1411, S3: 1, S3: 3, S3: 43
Coso D 513
Cossu A 1766
Costa A 723
Cowie F 422
Cremona F S3: 27
Cripps C 919
Crivellari D 353
Crombie C 947
Crucitti A 813
Cufer T 267
Cullen MH 1671
Cure H 693
Curigliano G 724, 1553, 1651
Cuzick J 1511
Cvitkovic F 397
Czuczman MS 109

D

D'Anjou J 1313
D'Ottavio A 179
D'Souza DP 1075
Da Prada GA 131
da Silva VD 1757
Dabouis G 59
Daffara F S2: 83
Dal Maso L 173, 331, 975, 1533
Daldrup-Link HE 479
Dams NL 1221
Damstrup L 745
Danesi R 69, 1301, 1553
Daniel C 957
Daniele B S3: 31
Darby S 1341
Daugaard G 431
Davidson NGP 1255
Dazord A 1461
Dazzi H 963
De Braud F 1553, 1651
de Castro J 1369
De Cicco C 724
de Deckere E S2: 51
De Giorgi U 1023
de Gramont A 675
de Haas V 587
de Kleijn EMHA 1107
De la Garza J 541
De Laurentiis M S3: 15
De Lucia L 199
De Marco S 1539
De Marinis F S3: 21
de Mulder PHM 726
De Oliveira CF 967
De Pas T 1553, 1651
De Placido S S3: 15
De Renzis C 1091
De Stefano V 1494
de Wit M 29
De Wolf-Peeters C 853
Deaglio S S2: 37
Debieuvre D 957
Debruyne C 1359
Debuire B 1439
Del Mastro L 373, 505, 1097
del Río E 1699
Del Tacca M 69, 1301, 1553
Delaunoit T 869
Delecroix V 909
Dell'Anna T 1179
Dell'Oro S 1693
Delle Fave G S2: 13
Delmas-Marsalet B 1439
Delobel-Deroide A 1313
Delord JP 1019
Delozier T 1677
Delrio P S3: 27
Delvart V 1005
Demirci S 1011
Demirkazık A 1011
Dentico P 519
Depierre A 1375, 1677
Depisch D 183, 709, 1269
Deporte-Fety R 909
Desiderio F 1179
Devogelaere RC 1221
Di Costanzo F 1331, 1737
Di Leo A 615, 1081, 1757
Di Mario A 1494
Di Paolo A 1301
Di Raimondo F 621
di Sant'Agnese PA S2: 135
Diab S 605
Dias R S1: 43
Dicuonzo G 132
Diehl V 471, 661, 1307
Diéras V 231
Dietrich P-Y 259, 953
Diez O 1699
Dimopoulos MA 991, 1417
Dinçol D 1011
Dirix LY 259
Djulbegovic B 1611
Doga M S2: 89
Dogliotti L 1331, S2: 1, S2: 73, S2: 105, S2: 153, S2: 159
Dolci S 615, 1081
Doll R 1341
Dombernowsky P 81, 647, 1067

Domènech M 1699
Domenge C 1595
Donati S 69, 1097
Dorta J 1369
Dorval T 231
Dove Edwin I 151
Dowling AJ 773
Dragosics B 937
Dreher E 819
Droz J-P 1313
Drummond M 947
du Bois A 1115
Ducreux M 397, 535, 869, S2: 79
Dudczak R S2: 41
Dueñas-Gonzalez A 541
Dufour P 865
Dugan M 259, 1527
Duijvestijn JA 115
Dukers DF 209, 779
Dumont J 1313
Dumontet C 433
Dunleavy TL 549
Dunn SM 365
Dunphy FR 549
Dunst J 1619
Duvillard P 869

E
Ebert A S1: 97
Ebsen M 1169
Eckhardt SG 285, 1631
Economou O 991
Edwards MJJ 1327
Eggermont AMM 9, 1663
Egorin MJ 119
Egreteau J 1321
Ehninger G 471
Eichelmann K 47
Eiermann W 1527, S1: 57
El-Gazzaz G 161
El-Weshi AN 53
Elbracht M 859
Elfring GL 1631
Elias D 869, S2: 79
Elledge R 605
Ellis M 1527
Emile J-F 1005, 1439
Eng C 1743
Engert A 661, 1307, 1504
English DR 761
Equitani F 203
Erekul S 1011
Eremin J 1527
Eriksson B 1383
Erlich R 1173
Erlichman C 389, 627, 701
Ermani M 255
Ernst DS 773
Escudero P 1061
Escudier B 1497
ESMO Guidelines Task Force 1047, 1049, 1051, 1053, 1055, 1057, 1059, 1205, 1209, 1211, 1213, 1215, 1217, 1219
Espina BM 457
Espinosa E 1369
Ettore F 841
Evans MT 497
Evans TRJ 1407
Evers K S1: 97
Extra J-M 231
Ezzat AA 53

F
Faber MN 1289
Fabi A 1539
Fabiani L S2: 105
Fabro M 1411
Fahlke J 47
Fakih M 1173
Falcone A 1301, 1331
Falconi M S2: 101
Falini B 1445
Farrokhi P 1439
Fassotte MF 825
Fatouros M 715
Favalli G S3: 37
Favre C 69
Feliu J 1369
Fenaroli P 1505
Ferone D S2: 125
Ferrante P 693
Ferrari A 1157, 1163
Ferrari C 1601
Ferrari L S2: 69
Ferrari S 1145
Ferreira CG 799
Ferreira F 615
Ferreira Filho AF 1757
Ferrera P 767
Ferrero JM 841
Ferretti G 724
Ferrucci PF 987
Ferry DR 161, 245
Fervers B 1037
Fey MF 981
Fickers MMF 115
Fiebiger W 183, 421, 937, 1269, 1281
Fiere D 451
Filipovich E 1061
Fillat C 379
Fillet G 825
Fillola G 1019
Finke J 655
Fiorentini G 1023
Fizazi K 535, 1025, 1265
Fjällskog M-L 1383
Fléchon A 275
Fleming GF 1743
Flesch H 643
Flesch M 675
Flikweert DC 115
Florentino R 541
Floriani I 1179
Focan Ch 1081, 1683
Fodor M 1403
Fogli S 1553
Follath F 963
Fölsch UR 1619
Fonck M 675
Fontana D S2: 153, S2: 159
Foran JM 1327
Ford HT 685
Forman D 145
Formanek M 937
Formento JL 841
Forni M 953
Forstpointner R 1393
Fossati-Bellani F 1157
Fossella FV 739
Fountzilas G 593, 1231, 1545
Fournel P 59
Fox RM 1455
Fraccon AP 187
Franceschelli L 1651
Franceschi S 173, 327, 331, 337, 975, 1533, 1589
Franceschi T 187
François E 397
Francoual M 841
Franklin J 471
Franzius C 479
Frassinetti L 1331
Frassoldati A 1539
Fraternali Orcioni G 1445
Frenay M 217
Frénoy N 1439
Frevola L 1097
Freyer G 1461, 1677
Frobert JL 1411
Füger B S2: 41
Fullarton GM 1407
Fumoleau P 847, 909, 1289, 1643

G
Galani E 991
Galanis E 701
Galimberti V 997
Gallardo JO 1403
Gallo C S3: 49
Gallus S 975
Gamargo C 1403
Gamberi B 1445
Gamberi G 75
Gamelin E 1411
Gancberg D 615, 1081
Gandola L 1157
Gans S 1359
Ganser A 569, 1489

Garassino I S2: 119
Garcia del Muro X 487
Garcia-Vargas J 1407
Gardiman M 255
Garufi C 179
Gasperoni S 1331, 1737
Gassel HJ 321
Gastaut JA 513
Gatzemeier U 835
Gatzemeier W 723
Gaudray P S2: 3
Gaulard Ph 1749
Gautier-Gougis MS 807
Gazet J-C 685
Gebauer T 47
Gebbia V 767
Gebski V 1711
Gedlicka C 1269
Gelmon K S1: 43
Gentile AL 519
Genuardi M 813
George Ch 89
Georges C 643
Georgoulias V 101, 193, 463, 793
Gérard J-P 397
Germà-Lluch JR 487
Geuenich S 1393
Gez E 227
Giaccone G 209, 799, 1359, 1567
Giacomini S 1145
Gianni AM 1693
Gianni L 1067, 1179, S1: 63
Gika D 991
Gil T 847
Gilbert MR 149
Giles GG 761
Giordani P 239
Giovanis P 1023
Giovannetti E 1553
Giovannini M 397
Gisselbrecht Ch 1749
Giustina A S2: 89
Giustolisi R 621
Glaholm JG 929
Glimelius B 1039
Göbel U 1619
Gobert Ph 1081
Godley PA 633
Goecke E 599
Gogas H 1545
Goldberg RM 389, 627, 701
Goldhirsch A 95, 353, 724
Goldschmidt E 1439
Goldwasser F 1005
Gómez-Foix AM 379
Gómez-Treviño A 379
Göner M 415
González Barón M 1369
Gonzalez A 541
Gordon L 109
Gore M 873
Gornet J-M 1005
Gorzegno G S2: 73, S2: 105, S2: 153
Gošev M S1: 95
Goss G 919
Goto M 1729
Gouva S 59
Gower NH 497
Grabenc M 1581
Graf N 311
Graffeo R 353
Granberg D 1383
Gray B 1711
Gray R 685
Graziano F 239
Greco F 69
Greenwich M 1611
Greif J 1127
Greim G 509
Greiner T 831
Grem JL 1581
Grgić M S1: 95
Grianti C 239
Gridelli C S3: 1, S3: 21
Griffin T 605
Grigg AP 1455
Grigoraki V 991
Grillo-López AJ 109
Grimfjärd P 1383
Grob TJ 981
Groen HJM 557, 787
Grollman F 1581
Grossman AB S2: 47
Grotenhermen F-J 1307
Grothey A 435
Grumett SA 575
Grundtvig Sorensen P 647
Grünwald V 1489
Guadagni S 1023
Guadarrama R 541
Guarneri V 69
Gubetta L S2: 159
Guenzi M 373
Guettier C 1439
Guitera-Rovel P 807
Gumà J 487
Gumus Y 1439
Gurney H 947
Gutschow K 1393
Gutterman L 1259

H

Haakenaasen U 1601
Haegele P 643
Hagemeister FB 923
Hahn EG 221, 1721
Hahn RG 1139
Haim N 227
Haioun C 1749
Haldemann A 941
Halford S 1399
Haller DG 278, 1139, 1575
Hamilton JM 123, 1581
Hammel P 675
Hammond LA 1631
Hanauske A 509, 835
Hanby AM 411
Hanke B 221
Hansen HH 431, 647
Hänsler J 1721
Hansson J S2: 145
Happich K 221
Haraf DJ 343
Harms D 311, 1619
Harper PG 1191, 1399, 1485
Harrington KJ 493
Harris AL 582, 1407
Harrison BR 549
Harte KJ 1075
Hartmann W 1375
Hasenclever D 471
Hauke R 831
Hawkins MJ 271
Heatley S 1433
Heimans JJ 259
Heinemann V 1393
Heinrich S 321
Hejna M 1281
Henner WD 1273
Henriksson R 259
Hense HW 1619
Henze G 1619
Herbst RS 739
Herd R 693
Herling C 1433
Herndon II JE 633
Herrstedt J 1037
Hess D 353
Hidalgo M 285
Hiddemann W 599, 1393
Hill D 1341
Himmler B 221
Hinojosa LM 541
Hirsch FR 647
Hoang-Xuan K 259
Hoctin Boes G 967
Hodges S 1631
Hodgkin E 245
Hofland LJ S2: 31, S2: 125
Hohenberger W 221, 1721
Holland JC 633
Hope M 1711
Hopper JL 761
Hossfeld DK 29, 1761
Houyau P 847
Howell J S1: 43
Howell SB 187

Hozo I 1611
Hsieh Y-Ch 1575
Hsu NY 1561
Hübel K 661
Huisman C 1567
Humblet YP 847, 1221, 1595
Humphrey R 389
Hussain SA 161, 245, 929
Hustinx R 825
Hynes NE S1: 9, S1: 21
Hyodo I 1133

I
Ibrahim EM 53
Ibrahim NK 1180
Içli F 1011
Inbar M 563
Inbar M 1127
Ingeberg S 647
Innocenti F 69
Inogés S 1479
Isla MD 1061
Isola J 1081

J
Jacobs HJM 1107
Jacobs RH 1743
Jacoulet P 957
Jagdev SP 1433
Jakić-Razumović J S1: 95
James ND 161, 929
Janssen-Heijen MLG 1295
Järvinen K 1239
Jarvinen T 1081
Jasmin C 1439
Jassem J 1375, 1677
Jelic S 1037
Jenkins DJA 173, 1533
Jeppesen N 647
Jerusalem G 825
Johnson W 761
Johnston A 1595
Jones J 89, 1259
Jones RS 681
Jones SE 605, 1247
Jonker JM 799
Jordanoglou J 463
Jost L 1037
Josting A 1307
Jouve M 231
Jung G-M 643
Junginger T 321
Jürgens H 479, 1619
Justice GR 457

K
Kaarteenaho-Wiik R 1239
Kakolyris S 101, 193, 463, 793
Kalbakis K 193, 793
Kalofonos Ch 1545
Kalofonos HP 1231, 1417
Kalogera-Fountzila A 1545
Kaltsas GA S2: 47
Kamina S 715
Kaminska J 1423
Kang WK 349
Kantarjian H 621
Kantarjian HM 885
Kao A 1561
Karabekios S 101
Karabelis A 249
Karapetis CS 1399, 1485
Kardamakis D 1231
Karnicka-Młodkowska H 1375
Karsenty J-M 1313
Karstens JH 1489
Kaufmann K 963
Kaufmann SH 627
Keating MJ 621
Keilholz U 105
Keitel-Wittig C 105
Keizer HJ 357, 1353
Kelly C 1595
Kemeny NE 501
Kendall CWC 1533
Kentenich Ch 1393
Kerbush T 787
Kern W 599
Kerr DJ 7, 161, 245, 575
Kessler R 957
Kettner E 47
Key TJ 1507
Khafaga YM 53
Khawaja HT 1399
Khoo K 919
Khoury P 605
Khuri FR 739
Kiamouris Ch 991, 1417
Kieffer I 819
Kiemeney LALM 1107
Kies MS 343
Kim DY 349
Kim WS 349
Kimmig R 1115
Kinnula V 1239
Kirchner EM 1169
Kirchner H 471
Kirchner J 1169
Klaassen D 919
Klee GG 389
Kletter K S2: 41
Kloke O 1037
Kluin-Nelemans JC 853
Knapp W 1605
Knauf W 105
Knight S 1255
Knippertz R 661
Knowling M 919
Knuffmann C 1761
Ko Y-H 349
Koch P 471, 1307
Köckerling F 1721
Köhne C-H 321, 435
Kolb F 807
Kolitz J 457
Kondo T 1121
Koralewski P 1677
Kornblith AB 633
Kornek GV 183, 421, 709, 1269, 1653
Kosmas C 793
Kosmidis P 249, 1231, 1545
Köster W 874
Köstler WJ 1281
Kottke-Marchant K 655
Kouroussis C 101, 463, 793
Kouvatseas G 991, 1231
Krainer M 1281
Krauss G 183
Krawczyk K 1375
Kraynak M 605
Kremens B 1619
Kreuser ED 105
Kreuzer K-A 981
Kristensen C 647
Kromelis P 605
Kröning H 47
Kruyt FAE 799
Krzakowski M 1375
Kuebler JPh 89, 1259
Kuhn JG 1631
Kühnel G 1605
Kurtaran A S2: 41
Kurtz JE 865
Kuske M 1489
Kuten A 227

L
La Vecchia C 173, 327, 331, 337, 733, 975, 1467, 1533, 1589
Laack E 1761
Laadem A 1411
Labar B S1: 95
Labianca R 13, 132, 1505, S3: 31
Lacave AJ 967
Lacevic M 1611
Lagrange J-L 1313
Lalli S S2: 95
Lamb H 1195
Lamberts SWJ S2: 1, S2: 31, S2: 125
Lambiase A 505
Lamers CBHW 1295
Lampert S 221
Landi B 675
Lane HA S1: 9, S1: 21
Lang F 709, 1269
Lang N 599
Langer SW 405

Langlois D 1411
Lanigan A S1: 23
Laplaige Ph 1411
Largillier R 841
Larrimer N 1259
Larsimont D 615, 1081
Lartigau E 807
Lasser P 869
Lassus M 1527
Lathan B 471, 1307
Latini L 277
Lau H 947
Laufman LR 89, 1259
Laws S 1247
Lazzi S 1766
Le Blanc S 1489
Le Chevalier T 535, 1667
Lebrun C 217
Ledermann JA 693
Lee CC 1561
Lee HG 349
Lee HJ 349
Legrand C 1359
Lehnert M 1619
Leider-Trejo L 563
Leimer M S2: 41
Lemanski C 397
Lemarié E 957, 1375, 1677
Léna H 59
Lenauer A 183, 709, 1269
Lenoir GM 1461
Leonardo E S2: 159
Leoncini L 1766
Leoncini O 131
Leone G 203, 1494
Leone R 187
Leong T 1015
Lepage E 1749
Lerchenmüller C 415
Lerner S 621
Letzer J 457
Leuschner I 311
Levi F 331, 733, 975, 1467
Levine AM 457
Levis A 203
Levite M S2: 19
Lewanski CR 493
Leyland-Jones B S1: 43
Li SR S2: 41
Ligneau B 1461
Lin CC 1561
Link T 719
Lionetto R 1097
Lippe P 277
Lippert H 47
Lissia A 1766
List MA 343
Little RF 123
Lizón J 1369
Llombart-Cussac A 1527
Lobelle J-P 1081
LoBuglio AF 109
Locatelli MC 1023
Locker PK 1631
Loeffler M 471
Lofts FJ 1407
Logan TF 1173
Lombard-Bohas C 275
Lombardi D 353
Lombardi F 1157
Longhi A 1145
Lopes G 1005
Lopez-Graniel C 541
Lorenz M 321
Lotz J-P 693
Louboutin JP 909
Louvet C 675
Lowe BA 1273
Lowndes S 685
Luboinski M 953
Lucas V 1411
Lucchini F 1467
Lucci-Cordisco E 813
Lück HJ 1115
Ludwig R 311
Lüftner DI 119
Luini A 997
Luksch R 1157
Lumbroso J 807
Lunardi G 1097
Luporsi E 397
Lyman GH 1611
Lymperopoulos E 715

M

Ma B 1015
MacCallum P 1327
Maccauro M S2: 51
Macdonald D 259
Machold K 937
Machover D 1439
Mackay HJ 1407
Madroszyk A 1321
Maecke HR 941
Maes B 853
Maffei R 1479
Magagnoli G 75
Magistrelli P 813
Magni P S2: 27
Mahmoudi M 1705
Maisano R 1091
Makinde V 685
Malafosse R 732, 887
Malaguti C 1601
Malamos N 793
Maldonado V 541
Malekmohammadi M 1393
Maloisel F 865
Maloney D 109
Maltoni M 289, 443, S3: 15
Mamelle G 807
Mancini MA 1163
Mancuso P 987
Mandalà M 95
Mandelli F 203
Manegold Ch 835, 1359
Manfrini M 75
Mann A 1127
Mansouri K 835
Mantovani G 199
Mantz CA 343
Manzione L 199, 669, S3: 49
Manzke O 1307
Marangolo M 1023
Maraninchi D 513, 693
Margulis A 807
Mari E 1179
Mari M S2: 153, S2: 159
Mariani L 997
Marien SA 1221
Marmor S 1127
Marolleau J-P 1749
Marrocco E 95, 724
Marrocco T S2: 37
Martí JL 1061
Martin G 1369
Martin JM 53
Martin L 1321
Martin M 1067
Martinelli G 353, 987
Martinetti A S2: 69
Martino B 203
Martoni A 519
Martus P 221, 1721
Marty M 1643
Marubini E 997
Marx GM 1191
Masi G 1301
Massa E 199
Massard G 643
Massimino M 1157
Matsumura Y 1729
Mattes E 321
Matthews S 919
Mauer AM 1743
Mauriac L 1247, 1527, 1677, 1683
Mavroudis D 101, 193, 463, 793
Mayordomo JI 1061
Mazo A 379
Mazzei T 519
McArdle CS 1194
McConkey C 685
McCredie MRE 761
McDonald AC 1407
McDonald D 457
McInnes A 1407
McLaughlin P 109, 923

McMaster P 161
McVie JG 1033
Meazza C 1163
Mechine A 865
Meinders AE 1353
Mele A 203
Mele L 203, 1494
Meléndez J 541
Melillo L 203
Melioli G 505
Mellstedt H 1037
Meltorn M 745
Ménard S S1: 15
Menconi MC 69
Mende T 1761
Menon H 1493
Menssen HD 105
Mercadé E 379
Mercier S 807
Mercier, J 1313
Mercuri M 75, 1145
Merimsky O 1127
Merli M 75
Merrouche Y 1321, 1643
Mery E 1019
Mesiti M 1091
Messina M 1067, 1075
Meyer C 865
Meyer F 47
Meyer T 1705
Mianulli AM 1179
Michel J 1081
Michel P 397
Michelotti A 1097
Midgley R 575
Miglietta L 1023
Migliori M S2: 95
Milano G 841
Miles DW 411, 1247
Miller LL 1575, 1631
Milleron B 957
Minami Y 1121
Minasi JS 681
Minchella I 95
Mingrone W 987
Mini E 519, 1301
Mirabel X 397
Mirza DF 161
Misra SC 1439
Misset J-L 1411
Mittal B 343
Miyata Y 1133
Moczygemba J 605
Moebus V 1115
Moffitt DD 929
Mohar A 541
Moiseyenko V 1247
Molendini L 75
Mollers M 1359
Monfardini S 255
Monnerat C 875
Monnier A 847
Montcuquet P 847
Montella M 337, 1589
Monti C 1601
Moore MJ 773
Moore T 89, 1259
Moreau L 957
Morel P 1749
Morgan S 1075
Mori M 1575
Mornex F 59
Moroz P 1711
Mosca A S2: 153, S2: 159
Moscetti L 1737
Mosconi P S3: 15
Mota A 541
Motoyama AB S1: 21
Motta M S2: 27
Mounier N 1749
Mrsić M S1: 95
Mueller HH 321
Mueller-Brand J 941
Mukherjee JJ S2: 47
Mulholland P 575
Mulholland PJ 245
Muñoz D 541
Munzone E 95
Muretto P 239
Murillo L 1061
Muro K 1729
Musumeci R 6
Myers A 457

N
Nackaerts KL 1221
Naidu SV 1075
Najjar F 825
Namer M 841
Nanni O 289
Nardi M 1539
Natale JJ 119
Nathwani B 457
Navarria P 1157
Negri E 173, 327, 337, 1467, 1533, 1589
Nelli F S3: 21
Nelstrop AE 1705
Neri G 813
Neve RM S1: 9
Neville AJ 773
Nicolaides C 1417
Nicum S 575
Nielsen D 81
Niemeyer C 1619
Niggemeyer O 859
Nilsson O S2: 63
Ninfo V 1163
Nisters-Backes H 1307
Nisticò C 179
Nobili S 519
Nóbrega S 525
Nolè F 95, 353
Nordlinger B 732, 887
Norol F 1439
Northcote AD 493
Nosari A 203
Novak J 847
Novak U 981
Novakova L 1375
Novotny C S2: 41
Nukiwa T 1121

O
O'Brien M 1375
O'Brien S 621
O'Doherty CA 497
O'Dwyer P 13
O'Reilly E 501
O'Shaughnessy JA 1247
Öberg K 1383, S2: 111
Ohtsu A 1133
Okuno SH 627
Olencki T 655
Olopade OI 895
Onur H 1011
Oppliger Leibundgut E 981
Orfeuvre H 1677
Orlandi E 1157
Orlandi L 1403
Orlandini C 69
Orlando L 95
Østerlind K 81, 647
Österreicher C 937
Osterwalder B 1247
Otero J 1411
Ott R 1495, 1721
Oudard S 847

P
Paccotti P S2: 83
Pack K 151
Paepke S 1527
Paesmans M 585, 615, 1081
Paganelli G 724
Pagani O 353
Pagano L 203, 1494
Paillot N 957
Paillotin D 59
Palangié T 231
Palmer JL 923
Palmeri S 767
Palmieri G 1766
Panayiotidis P 991
Panoussaki E 1231
Panzarella T 773
Panzini I 1179
Paoloni FP 1539, 1737

Paolucci G 1479
Papadakis E 463
Papadimitriou Ch 991
Papadopoulos S S1: 97
Papakostas P 249, 1545
Papaldo P 1097, 1539
Papotti M S2: 115
Parache R-M 1313
Parazzini F 337
Paridaens R 39
Parisi V S3: 27
Park CH 349
Park K 349
Parmeggiani U S3: 27
Parpinel M 173, 1533, 1589
Parquet N 1439
Parsch H 221
Pas HH 115
Pasini F 187
Patel T 89, 1259
Patri P S2: 41
Patti G 132
Paul J 1407
Paulussen M 1619
Pavlidis N 715, 1037, 1231
Pazzagli I 69
Peake D 929
Peccatori F 987
Pectasides D 1417
Pedersen MW 745
Pederzoli P S2: 101
Pedraza E 953
Pedrazzoli P 131
Peiffert D 397
Pelucchi C 337
Penberthy DR 681
Penna Ch 887
Penning C 1595
Penz M 183, 421, 709, 937
Pereira T 525
Pergolizzi S 1091
Pericay C 1699
Pérol M 59
Perrocheau G 909
Perrone F S3: 21
Peruzzotti G 95, 724
Peschel C 719
Pession A 1479
Peters AM 493
Peters GJ 209, 779
Peters LJ 1015
Peters UR 981
Peterse H 1765
Petit RG 1631
Petit T 643
Petruska PJ 549
Petti MC 203
Pfisterer J 1115
Pfreundschuh M 471
Philip T 693
Piana E 519
Piccaluga PP 1445
Piccart MJ 615, 847, 1081, 1195, 1255, 1683, S1: 1, S1: 89
Picci P 75, 1145, 1601
Piccioli M 1445
Pichert G 895
Pico J-L 953
Pidlich J 1269
Pierce WC 1273
Pierga JY 231
Pietra G 505
Pignata S S3: 37
Pileri A 1693
Pileri SA 1445, 1479
Pilotti S 1693
Pincus SM 549
Pinedo HM 209, 779
Pinna G 255
Pinto AE 525
Pinto C 519
Pitot HC 389, 627, 701
Pivot X 1595
Pizza C 669
Pless M 941
Plunkett TA 411
Podolski P S1: 95
Poggi S 1445
Poggio M S2: 153
Popova N 723
Possinger K 119
Postmus PE 557, 799, 1359, 1567
Pouillart P 231, 1411, S1: 81
Poulsen HS 745
Preti HA 923
Pritchard J 1259
Pritchard KI 301
Pulsoni A 203
Punt CJA 9, 134, 1289, 1332, 1663
Puozzo C 1643
Pupa S S1: 15
Purkalne G 1037
Purohit OP 1433

Q

Quaas J 1115
Quaedvlieg PFHJ 1295
Queneau PE 1321
Quesnel B 1749
Quilliam J 685
Quoix E 59, 957

R

Raby N 1407
Raderer M 183, 421, 709, 937, 1269, S2: 41
Rades D 1605
Raeburn L 501
Ragazzini P 75
Ragni N 1023
Raina V 131
Rakhit A S1: 43
Ramaioli A 841, 1313
Ramanathan RK 1139
Ramlau R 1375, 1677
Rampling R 259
Ramponi S S3: 21
Rao S 259
Rarick MU 457
Ratain MJ 1743
Ravaioli A 1179, 1653
Ravdin P 1067
Ravic M 1289
Raymond L 573
Razis ED 593, 1545
Rebattu P 59
Reck T 1721
Reed E 876
Reeves J S1: 23
Reid J 701
Reimondo G S2: 83
Reinke F 569
Reiter A 1619
Repetto L S3: 49
Restek-Samaržija N S1: 95
Reyes F 1749
Reyes M 541
Reynès M 1005
Ricci P 373
Rich TA 681
Richart JM 549
Richel DJ 1255
Richter T 119
Rick O 1151
Ridwelski K 47
Riedel C 221
Riedel C 1721
Ries F 1081
Rieux C 1749
Rigatos G 793
Rigatos SK 101
Righi L S2: 115
Rigo P 825
Rimassa L S2: 119
Rinaldi DA 1631
Riofrio M 1265
Riou R 59
Rischin D 1015
Riva A 909
Roach R 89, 1259
Robain M 231
Roberts L 457
Robinet G 59, 1643
Robles E 541
Roche M 145
Rodriguez A 1369
Rodriguez Calvillo M 1479
Rodriguez GI 1631

Rodriguez MA 923
Rohr S 865
Rohrbach V 819
Roila F S3: 1, S3: 3
Rolland F 847
Romaguera JE 923
Rosati G 199, 669
Rosell R 1659
Rosenberg J 109
Rossi A 669, S3: 49
Rossi C 239
Rossi D 289
Rosso R 505, 1097, 1247, 1331
Rosti G 693
Rothenberg ML 1575, 1631
Rotilio A 255
Rotmensch J 1743
Rouas G 615
Rouas G 1081
Rousseau Y 1643
Rovella V 813
Rowinsky EK 605
Rubagotti A 1023
Rubens RD 411
Rubin I S1: 3
Rubin J 389, 627, 701
Rubio B 1403
Rudd RM 497
Rueffer U 471, 1307
Ruffié P 535, S2: 79
Ruggeri EM 1539
Ruiter DJ 9
Ruka W 1423
Rummeny EJ 479
Rupert R 89
Rustin GJS 1705
Ruszniewski P 675
Rutkowski P 1423
Ruxer R 1595
Ryberg M 81
Rybicki LA 655
Rysinska A 1423

S

Sa Cunha A 887
Sabattini E 1445
Sabbioni R 187
Saeger HD 321
Saenz A 487, 1061
Saeter G 1601
Safgren SL 701
Sagawa M 1121
Saghatchian M 535
Saijo N 1515
Saijo Y 1121
Saikia TK 1493
Saitoh H 1133
Salazar R 487
Saleh M 109
Salerno A 132
Saletti P 151
Saltz LB 501
Salvadori B 997
Salvagni S S3: 31
Samantas E 249, 991, 1231
Samuel D 1005
Samuels BI 923
Sánchez Heras B 1369
Sánchez M 487
Sandherr M 719
Sanguineti G 373
Santacaterina A 1091
Santini D 132
Santoro A S2: 119
Sanz J 1699
Sanz-Altamira PM 501
Sapino A S2: 37, S2: 115
Sappino AP 723
Sarra E 793
Sartini R 1479
Sartori S 1653
Sato G 1121
Sato M 1121
Savarese D 633
Savelli G S2: 51
Scambia G S3: 37
Scarpa A S2: 101
Scarpi E 289
Schaaf LJ 1631
Schalhorn A 599
Schaller G S1: 97
Scheithauer W 183, 421, 709, 1269, 1653
Schellens J 509
Schiff D 1173
Schiffer D S2: 131
Schilf A 1439
Schleicher J 1151
Schlichting C 569
Schlösser NJJ 557
Schlumberger M 1461, S2: 79
Schmidt D 311
Schmitz N 471
Schmoll HJ 1605
Schneeweiss B 183, 709
Schneider M 1595
Schneider T 1721
Schnell R 661
Schnetzler B 723
Schober O 479
Schöffski P 569, 1489
Schofield PE 365
Scholl S 231, S1: 81
Schramel FMNH 557
Schramm H 321
Schraub S 643
Schroeder W 1115
Schubart H 1151
Schuell B 709
Schuler B 1581
Schüll B 1653
Schulz A 661
Schwartsmann G 1757
Schwartz I 563
Schwartz Y 1127
Schweigert M 119
Schwella N 1151
Scicolone S 519
Scienza R 255
Sciuk J 479
Scoazec J-Y 275
Sculier JP 585
Sdrobolini A 1737
Segal M 1259
Sehested M 405
Seidman A S1: 43
Sekine I 1515
Selle F 675
Semiglazov V 1527
Semino C 505
Senac I 1643
Seregni E S2: 69
Seronie-Vivien S 1019
Serra P 289
Sertoli MR 505
Sessa C 353
Settineri N 1091
Severi G 761
Sevin D 1265
Sextro M 471
Seymour JF 1455
Seymour L 919
Seymour LW 245
Sezer O 119
Sganga P 199
Sguotti C 199, 1097
Shamash J 497
Shannon C 947
Sharma A 131, 1631
Shaw B 831
Shelton III CH 681
Shimada Y 1729
Shirao K 1133, 1729
Shiun SC 1561
Shmueli E 563
Sich D 187
Sieber M 1307
Siegert W 1151
Siehl J 105
Signorini A 505
Simon D 1749
Simonato L 975
Siu L 919
Skarlos D 1545
Skarlos DV 249, 1231
Skogseid B 1383
Skovsgaard T 81, 1255
Sledge G 1067

Sleijfer DT 787
Sliski AP 1075
Sloan JA 389, 627, 701
Smid K 209
Smir B 831
Smit EF 557, 787, 1567
Smith I SI: 75
Smyth J 509
Soares J 525
Soini Y 1239
Solorza G 541
Sommer H 1393
Song S-Y 349
Soria J-C 1667
Souglakos J 193
Soukop M 1407
Souquet PJ 59
Spadaro P 1091
Spaggiari L 1651
Span SW 799
Spatz A 807
Spielmann M 1265
Spiridonidis CH 89, 1259
Spreafico F 1157
Staak JO 661
Staccioli MP 239
Stahel R 1037
Stahl M 874
Staib P 661
Staib-Sebler E 321
Stanton P SI: 23
Starobinski M 1032
Staroselsky A 1127
Stathopoulos GP 101, 1545
Stavrakakis J 463
Stebbing J 873
Steele JPC 497
Steer CB 1191
Steffen J 1423
Steger A 1399
Steger C 501
Stein J 599
Stein M 227
Stemmer SM 1180
Stemmler HJ 599, 1393
Stern J 1595
Stevani I 373
Stewart JSW 493
Stivanello M S2: 73, S2: 105
Stock K 719
Stoppa AM 513
Strickland AH 1399, 1485
Stuart KE 501
Stupp R 259
Suc E 847
Sulkes A 1180
Sun SS 1561
Sun X 847
Sutcliffe R 685
Szelényi H 105
Szer J 1455

T
Taal BG 1295, 1765
Taeger D 1619
Tagliabue E SI: 15
Taguchi T 1133
Takimoto CH 1581
Talamini R 327, 331, 337, 1589
Talle K 1601
Tamburini M S3: 7, S3: 43, S2: 73, S2: 105, S2: 159
Tamsma JT 1353
Tanda F 1766
Tannock IF 23, 773, 919
Tarabuzzi R S2: 153, S2: 159
Tarantolo S 831
Tassinari D 1179, 1653
Tate J 655
Tattersall MHN 365, 883
ten Bokkel Huinink D 357
Teodorovic I 853, 967
Terenziani M 1157
Termine A S2: 73
Terrier-Lacombe M-J 1313
Terzoli E 179
Terzolo M S2: 83
Tesch H 471, 1307
Tesselaar MET 357
Testa A 767
Testori A 9
Theegarten D 1169
Théodore C 535, 1662
Theodore Ch 1313
Theunissen PHMH 115
Thiberville L 59
Thiel E 105
Thomas DA 885
Thomas M 873
Thomas P 59, 217
Thomas X 451
Thompson JF 365
Thomson E 1075
Thor A SI: 101
Thürlimann B 353
Timotheadou E 1545
Tirrito M 767
Tischkowitz MD 497
Tjan-Heijnen VCG 1359
Tkaczuk J 1019
Tobias JS 1075
Tobler A 981
Tomassetti P S2: 95
Tomassetti V S2: 95
Tomei F 327
Tomek S 1281
Tondini C 144, 1505
Tonelli R 1479
Tonini G 132
Torrego JC 1369
Torri V 1179
Torta M S2: 73, S2: 153
Tortochaux J 1595
Tosti ME 203
Tovar RB 1757
Traub T S2: 41
Traynor A 457
Tres A 1061
Tri!let-Lenoir V 1461, 1677
Tröger J 311
Tsavaris N 101, 193
Tsavdaridis D 1231, 1545
Tschan MP 981
Tsekeris P 1231
Tsiafaki P 193
Tsiafaki X 463
Tsiakopoulos E 1231
Tsianos E 715
Tucci A 669
Tuck D 1067
Tulpule A 457
Turi C 1479
Tzitzikas J 1231

U
Ulrich-Pur H 183, 421, 709, 1269
Ulusakarya A 1439
Üner A 1011
Usui K 1121

V
Vaccarella S 1533
Vaccaro A 179
Vaidya JS 1075
Valagussa P SI: 29
Valcke YJ 1221
Valentini M 239
van de Walle B 1289
van den Berg H 587
van den Bogaert W 39
van der Burg MEL 967
van der Lee I 557
van der Schoot CE 587
van der Valk P 799
van der Walt JD 1485
van Dijck JAAM 1107
van Gennip AH 569
van Groeningen CJ 209, 779
van Hagen PM S2: 125
Van Hazel G 1711
van Kuilenburg ABP 569
van Meerbeeck J 1359
van Mook WNKA 115
van Oosterom AT 39
van Putten JWG 557, 787
van Riel JMGH 209, 779
van Rijswijk R 787

Vandebroek JE 1221
Vandekerckhove F 39
Vanel D 1601
Vannozzi F 1301
Vansteenkiste JF 835, 1221
vd Kley JAMJ 115
Velten M 643
Vennin Ph 1411
Venturini M 373, 505, 1097
Verbeek ALM 1107
Vercherat C S2: 3
Verma S S1: 43
Vermorken JB 967, 1195
Vernillet L 909
Veronesi A 353
Veronesi P 997
Veronesi U 997
Verresen DA 1221
Verschuur HP 357
Vervessou E 991
Veslemes M 463
Vetter G 321
Viens P 693
Vile RG 493
Villalona-Calero MA 605, 1631
Vincenzi B 132
Vindevoghel A 1081
Vinholes J 1527
Vinnicombe S 1327
Virgolini I S2: 41
Visani G 203
Viscoli C 505
Visconti JL 549
Visser O 1295
Visvikis A 1417
Vlachonicolis J 463, 793
Voena C 1693
Vogelzang NJ 633
Voigt JJ 1019
Voigtmann R 1169
Vokes EE 343
Volk J 569
von Bubnoff N 719
von Hoff DD 605, 1631
von Pawel J 835
von Schilling C 719
Vos W 209, 779
Voûte PA 311, 1619
Vujanic GM 311

W

Wadler S 1595
Waggershauser T 599
Wagner A 1619
Waldherr C 941
Walker R 1327
Wallace DMA 929
Wanders J 509
Wanner P 573
Wasif Saif M 123
Weichselbaum RR 343
Weihkopf T 1489
Weil C 1067
Wein A 221, 1721
Weirich A 311
Wellbank H 493
Weynants P 835, 1221
White CA 109
Whittaker J 493
Wigler N 1127
Wilander E 1383
Wildfang I 1605
Wilke H 874
Wils J 13, 1331
Wilson WH 123
Wiltschke Ch 1281
Winograd B 1067
Witt ME 343
Witzig TE 701
Wogritsch S S2: 41
Wolf J 1307
Wouters D 209, 779
Wynendaele W 39

X

Xiros N 1417

Y

Yamada Y 1133, 1729
Yamao T 1729
Yáñez M 1403
Yarden Y S1: 3
Yee LK 1581
Yip D 1399, 1485
Yoon S-S 349
Younes A 923
Young AM 245
Yue N 259

Z

Zaknoen S 259
Zamboglou N 1231
Zamboni WC 119
Zampino MG 95
Zanetta G 967
Zanetti I 1163
Zangmeister J 89, 1259
Zaninelli M 187
Zappalà AR 179
Zatloukal P 1375
Zelek L 1265
Zervas K 991
Zeuli M 1737
Žgajnar J 723
Zidan J 227
Zielinski ChC 1281
Zinzani PL 1445, 1479
Zonnenberg BA 259
Zoubek A 1619
Zucali R 997
Zucca E 53, 987
Zuckerman E 633
Zwahlen D 981